Use of Volatile Compositions to Limit or Eliminate the Perception of Malodors - Patent application

Abstract

To provide a method of inhibiting, reducing or suppressing the perception of a malodor in a subject.SOLUTION: One aspect relates to the use of volatile compositions to limit, decrease or eliminate the perception of a malodor. Such compositions include at least one malodor antagonist optionally combined with perfuming ingredients. Such compositions, uses thereof in combination with delivery systems, and applications thereof to consumer products are also objectives of the present disclosure.SELECTED DRAWING: None

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Provisional Application No. 62 / 589,947, filed November 22, 2017, European Patent Application No. 18157790.9, filed February 21, 2018, U.S. Provisional Application No. 62 / 754,899, filed November 2, 2018, U.S. Provisional Application No. 62 / 589,841, filed November 22, 2017, European Patent Application No. 18156134.1, filed February 9, 2018, U.S. Provisional Application No. 62 / 754,849, filed November 2, 2018, U.S. Provisional Application No. 62 / 589,841, filed November 22, 2017, / 589,862, European Patent Application No. 18153067.6, filed January 23, 2018, U.S. Provisional Application No. 62 / 754,875, filed November 2, 2018, U.S. Provisional Application No. 62 / 589,857, filed November 22, 2017, European Patent Application No. 18158074.7, filed February 22, 2018, and U.S. Provisional Application No. 62 / 754,860, filed November 2, 2018, the entire contents of which are incorporated herein by reference in their entireties.

[0002] FIELD OF THEINVENTION Various aspects presented herein relate to the perfume industry.More specifically, various aspects presented herein relate to the use of volatile compositions to limit, reduce or eliminate the perception of malodor.Such compositions include at least one malodor antagonist, optionally combined with a fragrance component.Such compositions, their use in combination with delivery systems, and their application in consumer products are also objects of the present disclosure.

[0003] Background technology Malodors are present in many environments and are experienced in daily life. They can occur in any environment. Malodors include, for example, commercial and residential odors caused by waste, garbage cans, toilets, cat litter, and food handling and processing. Other examples include environmental sources such as bathrooms (including feces or urine), laundry areas, kitchens, and body odor. Malodors are often complex mixtures of multiple malodorous compounds, which typically may include various amines, thiols, sulfides, short chain aliphatic and olefinic acids, such as fatty acids, and their derivatives. For example, residential or body-related malodors typically include indole, skatole, dimethyl trisulfide (DMTS), p-cresol, and methanethiol (present in fecal malodors); piperidine and morpholine (present in urinary malodors); 1-octen-3-ol, geonol, butyric acid, nonen-1-ol, and borneol (present in laundry or mold malodors), pyridine and triethylamine (present in kitchen and garbage malodors); and short chain fatty acids such as 3-methyl-3-hydroxyhexanoic acid, 3-methylhexanoic acid, 3-2-methyl-2-hexenoic acid, 3-methyl-3-hydroxyhexanoic acid, 3-methyl-2-hexenoic acid, or 3-methyl-3-sulfanylhexanol (transpyrrole) (present in axillary malodors).

[0004] Malodors are unpleasant to humans, and therefore there is a demand for malodor counteracting (MOC) compositions and / or ingredients to reduce or suppress the perception of malodors. There are various approaches to achieve such goals using MOC compositions and / or ingredients, including masking, which refers to the suppression or reduction of the perception of malodors by various mechanisms, such as by MOC compositions and / or ingredients that have olfactory receptor antagonist activity.

[0005] The present disclosure provides a method for neutralizing malodor using a volatile composition that limits, reduces or eliminates the perception of malodor.Such a composition comprises at least one malodor antagonist, optionally combined with a fragrance component.Such compositions, their use in combination with delivery systems, and their application in consumer products are also objects of the present disclosure.

[0006] Summary of the Invention One aspect provided herein is a method of inhibiting, reducing, or suppressing the perception of malodor in a subject, comprising administering to a subject a compound selected from the group consisting of (1RS,6RS,11RS)-2,2,9,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,2,7,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-2-en-6-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-6-yl acetate, 1,5, 10,10-Tetramethylspiro[5.5]undec-3-en-11-yl acetate, 2,3,9,9-Tetramethylspiro[4.5]decane-10-yl)acetate, (5,10,10-trimethylspiro[5.5]undec-2-en-11-yl)formate, (3,5,10,10-Tetramethylspiro[5.5]undec-2-en-11-yl)acetate, (2,3,9,9-Tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (9,9-Dimethylspiro[4.5]dec-2-en-10-yl ) acetate, 10-methoxy-9,9-dimethylspiro[4.5]dec-2-ene, 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol, 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, mixture of 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol and 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, 2,4,8-trimethylspiro[5.5]undec-3-en-11 -ol, 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, a mixture of 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol and 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, 3-methyl-5-propan-2-ylspiro[5.5]undec-2-en-11-ol, 11-methylspiro[5.5]undecane-5-ol, 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 4,10,10-trimethylspiro[5.5]Undec-3-en-11-ol, mixture of 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol and 4,10,10-trimethylspiro[5.5]undec-3-en-11-ol, [2,2-dimethyl-1-(2,4,6-trimethylcyclohex-3-en-1-yl)propyl]acetate, [2,2-dimethyl-1-(2,4,6-trimethylcyclohexyl)propyl]acetate, (1RS)-2,2-dimethyl-1-[(1SR,2SR)-2-methylcyclohexyl]propyl acetate, 9,9-dimethylspiro[4.5]dec-2-en-10-ol, 2,3,9,9-tetramethylspiro[4.5]decan-10-ol, (2,2,3,3,9,9-hexamethylspiro[4.5]decan-10-yl)acetate, 9-methoxy-8,8-dimethylspiro[4.4]non-2-ene, (8,8-dimethylspiro[4.4]non-2-en-9-yl)acetate, 2,3,8,8-tetramethylspiro[4.4]non-2-en-9-one, 2,3,9,9-tetramethylspiro[4.5]dec- 2-en-10-ol, 4-methoxy-3,3-dimethylspiro[4.4]nonane, (4,9,9-trimethylspiro[4.5]dec-2-en-10-yl)acetate, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-ol, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)formate, (2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (+-)-2,3-dimethylspiro[4.5]dec-2-en-6-yl acetate , (4~{S},5~{R},6~{S},11~{S})-4,11-dimethylspiro[5.5]undecan-5-ol, 9,9-dimethylspiro[4.5]dec-2-en-10-one, 2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 1,1´,1´,5-tetramethyl-2´-methylidenespiro[6-oxabicyclo[3.1.0]hexane-3,3´-cyclohexane], 4,9,9-trimethylspiro[4.5] Dec-2-en-10-one, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-one, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-one, 2-but-3-en-2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one, 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2-but-3-en- Mixture of 2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one and 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol and 2,2-dimethyl-1- Mixture with (3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-ol, 1-methoxy-2,6-dimethyl-1-prop-2-enylcyclohexane, 1-(3-methylbut-2-enyl)cyclohex-2-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, A mixture of methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate and methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-ol, 1-(2,6-dimethylcyclohex-3-en-1-yl)-2,2-dimethylpropan-1-ol, 1-(2-methyl-4-tricyclo[5.2.1.0. 1,5 ]decanyl)ethyl acetate, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0 1,5]decanyl)ethyl acetate, 1-((1R,3S,3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)ethanone, 2,3,4-trimethyltricyclo[5.2.1.0^{1,5}]decane-4-carbaldehyde, (2,3,4-trimethyl-4-trimethyl 1-((3aS,6S)-2,3-dimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one oxime, 1,3-dimethyloctahydro-3a,6-methanoindene-1-carbaldehyde oxime, ~{N}-[1-[(1~{R},7~{R})-2,3,4-trimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)methyl acetate 1,5 ]decanyl]ethylidene]hydroxylamine, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethyl acetate, 1-[(1RS,2RS,4SR,7RS)-2,3,4-trimethyltricyclo[5.2.1.0 1. ~]dec-4-yl)ethanone, (E / Z)-1-[(1RS,7RS)-2,3-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone oxime, (E / Z)-1-[(1S,7S)-2,3,4-trimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethanone oxime, (E / Z)-1-((3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethanone oxime, (+-)-1-(3-methyloctahydro-3a,6-methanoinden-1-yl)ethyl acetate, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, 1-2,6,6-trimethyl-3-cyclohexen-1-yl-2-buten-1-one, 2-tert-butylphenol, 5-methyl-2-(propan-2-yl)phenol, nona-2,6-dienal, 1,1-diethoxy-3,7-dimethylocta-2,6-diene, 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde, 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene; 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, 3-(4-te rt-Butylphenyl)propanal, (4R,4aS,6R)-4,4a-dimethyl-6-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one, geranyl acetate, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-ethoxy-5-prop-1-enylphenol, 2,6,6,8-tetramethyl-9-oxatetracyclo[5.4.1.0^{1,5}.0^{8,10}]dodecane, nonyl aldehydes, isobutylquinoline, cyclopentadec-4-en-1-one, (-)-(R)-3,7-dimethyl-6-octenenitrile, 2-methyl-5-propan-2-ylphenol, isopropylquinolone, 5-hexyl-2-methylpyridine, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 2-pentylcyclopentan-1-one, 4-(2,6,6-trimethylcyclopentan-1-one, 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one; 2,4-dimethylcyclohex-3-enecarbaldehyde; phenylethylol;. 3,7-Dimethylocta-2,6-dienal, (2,2,2-trichloro-1-phenylethyl)acetate, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one, phenylethyl acetate, 7-hydroxy-3,7-dimethyloctanal, methyl citral, 6,10-dimethylundeca-5,9-dien-2-one, 2-ethoxy-5-prop-1-enylphenol, (4-methyl-4 -phenylpentan-2-yl)acetate, (+-)-3-methylcyclopentadecanone, 1-(4,8-dimethyl-12-methylidenecyclododeca-4,8-dien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-1,5,9-trien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-2,5,9-trien-1-yl)ethanone, cyclododecanone, (Z)-3,4,5, 6,6-Pentamethylhept-3-en-2-one, 1,4-Dioxacyclohexadecane-5,16-dione, Pentanol, Oxacyclohexadecane-2-one, 1,1,2,3,3-Pentamethyl-2,5,6,7-tetrahydroinden-4-one, (+-)-Perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, 2,3,3-Trimethyl-2H-inden-1-one, 4-(4,8-Dimethyl) Nona-3,7-dienyl)pyridine, 4-[(1~{R},3~{R},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one; 4-[(1~{S},3~{S},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one, (+)-(1R,7R)-10,10-dimethyl-tricyclo[7.1.1.0(2,7)]undec-2-en-4-one, (9 E)-Cycloheptadec-9-en-1-one; 8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2,3,5,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2,3,4,5,6,7-hexahydro-1~ {H}-Naphthalene-2-carbaldehyde;2,2-dimethyl-octahydro-1~{H}-2,4~{a}-methanonaphthalen-8-one;2,4~{a},8,8-tetramethyl-1~{a},2,4,5,6,7-hexahydro-1~{H}-cyclopropa[j]naphthalen-3-one;2,6,6,8-tetramethyltricyclo[5.3.1.0 1,5 ]undecane-9-one, (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-3,6,8,8-tetramethyloctahydro-1H-3a,7-methanoazulen-6-ol, (1RS,2SR,5RS,7RS,8SR)-5-methyltricyclo[6.2.1.0~2,7~]undecane -4-one (A) + (1RS,2SR,5SR,7RS,8SR)-5-methyltricyclo[6.2.1.0~2,7~]undecan-4-one (B), ethyl 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, ethyl 4,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, (2-methyl-2-indanyl)methylacetate Tart, 2-pentylcyclopentan-1-one, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexanone, phenethyl alcohol, diethyl 1,4-cyclohexanedicarboxylate, (+)-(R)-3,7-dimethyl-6-octenal, 3,5,6-trimethyl-3-cyclohexene-1-carbaldehyde (A) + 2,4,6-trimethyl-3-cyclohexene-1-carbaldehyde (B), 3,7-dimethylocta-2,6-dienal, 3-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde (A) + 4-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde, (4 Z ,8E )-13-Oxabicyclo[10.1.0]trideca-4,8-diene, (4E,8E)-4,8-cyclododecadien-1-one (A) + (4E,8Z)-4,8-cyclododecadien-1-one (B) + (4Z,8E)-4,8-cyclododecadien-1-one (C), 13-Oxabicyclo[10.1.0]trideca-4,8-diene, 2,2,7,7-tetramethyltricyclo[6.2.1.0~1,6~]undecan-6-ol, (+)-(1S,2S ,3S,5R)-2,6,6-trimethylspiro[bicyclo[3.1.1]heptane-3,1´-cyclohexane]-2´-en-4´-one, (5RS,6RS)-2,6,10,10-tetramethyl-1-oxaspiro[4.5]decan-6-ol, (2,2,2-trichloro-1-phenylethyl)acetate, patchouli oil, (1~{S},3~{S},6~{R},7~{R},8~{S})-2,2,6,8-tetramethyltricyclo[5.3.1.0 3,8]undecan-3-ol, (4S,4aS,8aR)-4,8a-dimethyl-1,2,3,4,5,6,7,-octahydronaphthalen-4a-ol, benzyl formate, (+-)-1-phenylethyl acetate, 3-phenyl-1-propanol, [cis-4-(2-propanyl)cyclohexyl]methanol, 2-methyl-2-indanmethanol, (2-methyl-2-indanyl)methyl acetate, (+-)-5-ethyl-2-methyl-2-indanmethanol, 5-methyl-2 -indanmethanol, (+-)-2-methoxymethyl-2,5-dimethylindan, 2,5,6-trimethyl-2-indanmethanol, (+-)-(2,4,5-trimethyl-2,3-dihydro-1H-inden-2-yl)methanol, (+-)-2-ethyl-5-methyl-2-indanmethanol, (+-)-2,4-dimethyl-2-indanmethanol, (+-)-2,4,6-trimethyl-2-indanmethanol, (+-)(2,7-dimethyl-1,2,3,4-tetrahydro- (+-)-(2,6-dimethyl-1,2,3,4-tetrahydro-2-naphthalenyl)methanol, (+-)-(5-methoxy-2-methyl-2,3-dihydro-1H-inden-2-yl)methanol, 2,2-dimethyl-3-phenyl-1-propanol alcohol, (+-)-1,2,6-trimethyl-2-indanethanol, (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxy (isomer A) + (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxine (isomer B) (A+B), 4-t-butylcyclohexanone, 1-(2,2-dimethyl-6-methylidenecyclohexyl)pent-1-en-3-one; 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohexen-1-yl)pent-1-en-3-one;1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, 2,2-dimethyl-4-phenyl-1,3-dioxolane, (+-)-2-((methoxymethoxy)methyl)-2,5-dimethyl-2,3-dihydro-1H-indene, amyl phenylacetate, 3-phenylbutanal, 2,4-dimethyl-4-phenyloxolane, 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-methyl-3-(4-methylphenyl)propanal, 3-methyl-5-phenylpentanol contacting the subject with at least one compound selected from the group consisting of tanal, (+-)-(2E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 4,5,6,7,8,9,10,11,12,13-decahydrocyclododeca[d][1,3]oxazole, and combinations thereof; Methods are provided in which at least one compound is contacted in an amount sufficient to inhibit, reduce, or suppress the perception of malodor by a subject.

[0007] In one embodiment, the contacting inhibits at least one olfactory receptor in the subject.

[0008] In one embodiment, the at least one olfactory receptor is a butyric acid olfactory receptor.

[0009] In one embodiment, the at least one olfactory receptor is a geonol olfactory receptor.

[0010] In one embodiment, the at least one olfactory receptor is a 1-octen-3-ol olfactory receptor.

[0011] In one embodiment, the at least one olfactory receptor is an indole / skatole olfactory receptor.

[0012] In one embodiment, the at least one olfactory receptor is a DMTS olfactory receptor.

[0013] One embodiment provided herein is a method of inhibiting at least one olfactory receptor in a subject, comprising administering to a subject an olfactory receptor selected from the group consisting of (1RS,6RS,11RS)-2,2,9,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,2,7,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-2-en-6-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-6-yl acetate, 1,5,1 0,10-Tetramethylspiro[5.5]undec-3-en-11-yl acetate, 2,3,9,9-Tetramethylspiro[4.5]decane-10-yl)acetate, (5,10,10-trimethylspiro[5.5]undec-2-en-11-yl)formate, (3,5,10,10-Tetramethylspiro[5.5]undec-2-en-11-yl)acetate, (2,3,9,9-Tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (9,9-Dimethylspiro[4.5]dec-2-en-10-yl) acetate, 10-methoxy-9,9-dimethylspiro[4.5]dec-2-ene, 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol, 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, mixture of 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol and 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol -ol, 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, a mixture of 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol and 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, 3-methyl-5-propan-2-ylspiro[5.5]undec-2-en-11-ol, 11-methylspiro[5.5]undecane-5-ol, 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 4,10,10-trimethylspiro[5.5]Undec-3-en-11-ol, mixture of 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol and 4,10,10-trimethylspiro[5.5]undec-3-en-11-ol, [2,2-dimethyl-1-(2,4,6-trimethylcyclohex-3-en-1-yl)propyl]acetate, [2,2-dimethyl-1-(2,4,6-trimethylcyclohexyl)propyl]acetate, (1RS)-2,2-dimethyl-1-[(1SR,2SR)-2-methylcyclohexyl]propyl acetate, 9,9-dimethylspiro[4.5]dec-2-en-10-ol, 2,3,9,9-tetramethylspiro[4.5]decan-10-ol, (2,2,3,3,9,9-hexamethylspiro[4.5]decan-10-yl)acetate, 9-methoxy-8,8-dimethylspiro[4.4]non-2-ene, (8,8-dimethylspiro[4.4]non-2-en-9-yl)acetate, 2,3,8,8-tetramethylspiro[4.4]non-2-en-9-one, 2,3,9,9-tetramethylspiro[4.5]dec- 2-en-10-ol, 4-methoxy-3,3-dimethylspiro[4.4]nonane, (4,9,9-trimethylspiro[4.5]dec-2-en-10-yl)acetate, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-ol, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)formate, (2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (+-)-2,3-dimethylspiro[4.5]dec-2-en-6-yl acetate , (4~{S},5~{R},6~{S},11~{S})-4,11-dimethylspiro[5.5]undecan-5-ol, 9,9-dimethylspiro[4.5]dec-2-en-10-one, 2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 1,1´,1´,5-tetramethyl-2´-methylidenespiro[6-oxabicyclo[3.1.0]hexane-3,3´-cyclohexane], 4,9,9-trimethylspiro[4.5] Dec-2-en-10-one, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-one, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-one, 2-but-3-en-2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one, 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2-but-3-en- Mixture of 2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one and 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol and 2,2-dimethyl-1- Mixture with (3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-ol, 1-methoxy-2,6-dimethyl-1-prop-2-enylcyclohexane, 1-(3-methylbut-2-enyl)cyclohex-2-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, A mixture of methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate and methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-ol, 1-(2,6-dimethylcyclohex-3-en-1-yl)-2,2-dimethylpropan-1-ol, 1-(2-methyl-4-tricyclo[5.2.1.0. 1,5 ]decanyl)ethyl acetate, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0 1,5]decanyl)ethyl acetate, 1-((1R,3S,3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)ethanone, 2,3,4-trimethyltricyclo[5.2.1.0^{1,5}]decane-4-carbaldehyde, (2,3,4-trimethyl-4-trimethyl 1-((3aS,6S)-2,3-dimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one oxime, 1,3-dimethyloctahydro-3a,6-methanoindene-1-carbaldehyde oxime, ~{N}-[1-[(1~{R},7~{R})-2,3,4-trimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)methyl acetate 1,5 ]decanyl]ethylidene]hydroxylamine, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethyl acetate, 1-[(1RS,2RS,4SR,7RS)-2,3,4-trimethyltricyclo[5.2.1.0 1. ~]dec-4-yl)ethanone, (E / Z)-1-[(1RS,7RS)-2,3-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone oxime, (E / Z)-1-[(1S,7S)-2,3,4-trimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethanone oxime, (E / Z)-1-((3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethanone oxime, (+-)-1-(3-methyloctahydro-3a,6-methanoinden-1-yl)ethyl acetate, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, 1-2,6,6-trimethyl-3-cyclohexen-1-yl-2-buten-1-one, 2-tert-butylphenol, 5-methyl-2-(propan-2-yl)phenol, nona-2,6-dienal, 1,1-diethoxy-3,7-dimethylocta-2,6-diene, 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde, 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene; 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, 3-(4-te rt-Butylphenyl)propanal, (4R,4aS,6R)-4,4a-dimethyl-6-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one, geranyl acetate, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-ethoxy-5-prop-1-enylphenol, 2,6,6,8-tetramethyl-9-oxatetracyclo[5.4.1.0^{1,5}.0^{8,10}]dodecane, nonyl aldehydes, isobutylquinoline, cyclopentadec-4-en-1-one, (-)-(R)-3,7-dimethyl-6-octenenitrile, 2-methyl-5-propan-2-ylphenol, isopropylquinolone, 5-hexyl-2-methylpyridine, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 2-pentylcyclopentan-1-one, 4-(2,6,6-trimethylcyclopentan-1-one, 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one; 2,4-dimethylcyclohex-3-enecarbaldehyde; phenylethylol;. 3,7-Dimethylocta-2,6-dienal, (2,2,2-trichloro-1-phenylethyl)acetate, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one, phenylethyl acetate, 7-hydroxy-3,7-dimethyloctanal, methyl citral, 6,10-dimethylundeca-5,9-dien-2-one, 2-ethoxy-5-prop-1-enylphenol, (4-methyl-4 -phenylpentan-2-yl)acetate, (+-)-3-methylcyclopentadecanone, 1-(4,8-dimethyl-12-methylidenecyclododeca-4,8-dien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-1,5,9-trien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-2,5,9-trien-1-yl)ethanone, cyclododecanone, (Z)-3,4,5, 6,6-Pentamethylhept-3-en-2-one, 1,4-Dioxacyclohexadecane-5,16-dione, Pentanol, Oxacyclohexadecane-2-one, 1,1,2,3,3-Pentamethyl-2,5,6,7-tetrahydroinden-4-one, (+-)-Perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, 2,3,3-Trimethyl-2H-inden-1-one, 4-(4,8-Dimethyl) Nona-3,7-dienyl)pyridine, 4-[(1~{R},3~{R},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one; 4-[(1~{S},3~{S},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one, (+)-(1R,7R)-10,10-dimethyl-tricyclo[7.1.1.0(2,7)]undec-2-en-4-one, (9 E)-Cycloheptadec-9-en-1-one; 8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2,3,5,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2,3,4,5,6,7-hexahydro-1~ {H}-Naphthalene-2-carbaldehyde;2,2-dimethyl-octahydro-1~{H}-2,4~{a}-methanonaphthalen-8-one;2,4~{a},8,8-tetramethyl-1~{a},2,4,5,6,7-hexahydro-1~{H}-cyclopropa[j]naphthalen-3-one;2,6,6,8-tetramethyltricyclo[5.3.1.0 1,5 ]undecane-9-one, (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-3,6,8,8-tetramethyloctahydro-1H-3a,7-methanoazulen-6-ol, (1RS,2SR,5RS,7RS,8SR)-5-methyltricyclo[6.2.1.0~2,7~]undecane -4-one (A) + (1RS,2SR,5SR,7RS,8SR)-5-methyltricyclo[6.2.1.0~2,7~]undecan-4-one (B), ethyl 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, ethyl 4,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, (2-methyl-2-indanyl)methylacetate Tart, 2-pentylcyclopentan-1-one, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexanone, phenethyl alcohol, diethyl 1,4-cyclohexanedicarboxylate, (+)-(R)-3,7-dimethyl-6-octenal, 3,5,6-trimethyl-3-cyclohexene-1-carbaldehyde (A) + 2,4,6-trimethyl-3-cyclohexene-1-carbaldehyde (B), 3,7-dimethylocta-2,6-dienal, 3-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde (A) + 4-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde, (4 Z ,8E )-13-Oxabicyclo[10.1.0]trideca-4,8-diene, (4E,8E)-4,8-cyclododecadien-1-one (A) + (4E,8Z)-4,8-cyclododecadien-1-one (B) + (4Z,8E)-4,8-cyclododecadien-1-one (C), 13-Oxabicyclo[10.1.0]trideca-4,8-diene, 2,2,7,7-tetramethyltricyclo[6.2.1.0~1,6~]undecan-6-ol, (+)-(1S,2S ,3S,5R)-2,6,6-trimethylspiro[bicyclo[3.1.1]heptane-3,1´-cyclohexane]-2´-en-4´-one, (5RS,6RS)-2,6,10,10-tetramethyl-1-oxaspiro[4.5]decan-6-ol, (2,2,2-trichloro-1-phenylethyl)acetate, patchouli oil, (1~{S},3~{S},6~{R},7~{R},8~{S})-2,2,6,8-tetramethyltricyclo[5.3.1.0 3,8]undecan-3-ol, (4S,4aS,8aR)-4,8a-dimethyl-1,2,3,4,5,6,7,-octahydronaphthalen-4a-ol, benzyl formate, (+-)-1-phenylethyl acetate, 3-phenyl-1-propanol, [cis-4-(2-propanyl)cyclohexyl]methanol, 2-methyl-2-indanmethanol, (2-methyl-2-indanyl)methyl acetate, (+-)-5-ethyl-2-methyl-2-indanmethanol, 5-methyl-2 -indanmethanol, (+-)-2-methoxymethyl-2,5-dimethylindan, 2,5,6-trimethyl-2-indanmethanol, (+-)-(2,4,5-trimethyl-2,3-dihydro-1H-inden-2-yl)methanol, (+-)-2-ethyl-5-methyl-2-indanmethanol, (+-)-2,4-dimethyl-2-indanmethanol, (+-)-2,4,6-trimethyl-2-indanmethanol, (+-)(2,7-dimethyl-1,2,3,4-tetrahydro- (+-)-(2,6-dimethyl-1,2,3,4-tetrahydro-2-naphthalenyl)methanol, (+-)-(5-methoxy-2-methyl-2,3-dihydro-1H-inden-2-yl)methanol, 2,2-dimethyl-3-phenyl-1-propanol alcohol, (+-)-1,2,6-trimethyl-2-indanethanol, (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxy (isomer A) + (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxine (isomer B) (A+B), 4-t-butylcyclohexanone, 1-(2,2-dimethyl-6-methylidenecyclohexyl)pent-1-en-3-one; 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohexen-1-yl)pent-1-en-3-one;1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, 2,2-dimethyl-4-phenyl-1,3-dioxolane, (+-)-2-((methoxymethoxy)methyl)-2,5-dimethyl-2,3-dihydro-1H-indene, amyl phenylacetate, 3-phenylbutanal, 2,4-dimethyl-4-phenyloxolane, 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-methyl-3-(4-methylphenyl)propanal, 3-methyl-5-phenylpentanol contacting the subject with at least one compound selected from the group consisting of tanal, (+-)-(2E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 4,5,6,7,8,9,10,11,12,13-decahydrocyclododeca[d][1,3]oxazole, and combinations thereof; At least one olfactory receptor is selected from the group consisting of butyrate olfactory receptor, geonol olfactory receptor, 1-octen-3-ol olfactory receptor, indole / skatole olfactory receptor, and DMTS olfactory receptor; and The method includes contacting at least one compound in an amount sufficient to inhibit at least one olfactory receptor.

[0014] In one embodiment, inhibition of at least one olfactory receptor inhibits, reduces or prevents the perception of malodors in a subject.

[0015] In one aspect, the malodor is selected from the group consisting of toilet malodor, laundry malodor, mold malodor, and sweat malodor.

[0016] In one embodiment, at least one olfactory receptor is a butyric acid olfactory receptor. In one embodiment, the butyric acid olfactory receptor is selected from the group consisting of OR51E1 olfactory receptor and Olfr558 olfactory receptor.

[0017] In one embodiment, the at least one compound that inhibits the butyric acid olfactory receptor is (1RS,6RS,11RS)-2,2,9,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,2,7,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-2-en-6-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-6-yl acetate, 1,5,10,10-tetramethylspiro[5.5]udec-1 ... undec-3-en-11-yl acetate, 2,3,9,9-tetramethylspiro[4.5]dec-10-yl)acetate, (5,10,10-trimethylspiro[5.5]undec-2-en-11-yl)formate, (3,5,10,10-tetramethylspiro[5.5]undec-2-en-11-yl)acetate, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (9,9-dimethylspiro[4.5]dec-2-en-10-yl)acetate, 10-methoxy-9,9-dimethylspiro[ 4.5]dec-2-ene, 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol, 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, mixture of 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol and 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol, 2,9,11-trimethylspiro[5.5]undec-9 ...9,11-trimethylspiro[5.5]undec-9-en-11-ol, 2,9,11-trimethylspiro[5.5]undec-9-en-11-ol, 2,9,11-trimethylspiro[5.5]undec-9-en-11-ol, 2,9,11-trimethylspiro[5.5]undec-9-en-11-ol, 2,9,11-trimethylspiro[5.5]undec-9- 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol and 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, 3-methyl-5-propan-2-ylspiro[5.5]undec-2-en-11-ol, 11-methylspiro[5.5]undecane-5-ol, 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 4,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 3,10,10-trimethylspiro[5.5]Undec-3-en-11-ol and 4,10,10-trimethylspiro[5.5]undec-3-en-11-ol mixture, [2,2-dimethyl-1-(2,4,6-trimethylcyclohex-3-en-1-yl)propyl]acetate, [2,2-dimethyl-1-(2,4,6-trimethylcyclohexyl)propyl]acetate, (1RS)-2,2-dimethyl-1-[(1SR,2SR)-2-methylcyclohexyl]propyl acetate, 9,9-dimethylspiro[4.5]dec-2-en-11-ol mixture, 2,3,9,9-Tetramethylspiro[4.5]dec-10-ol, (2,2,3,3,9,9-Hexamethylspiro[4.5]dec-10-yl)acetate, 9-Methoxy-8,8-dimethylspiro[4.4]non-2-ene, (8,8-Dimethylspiro[4.4]non-2-en-9-yl)acetate, 2,3,8,8-Tetramethylspiro[4.4]non-2-en-9-one, 2,3,9,9-Tetramethylspiro[4.5]dec-2-en-10-ol, 4-Methoxy- 3,3-Dimethylspiro[4.4]nonane, (4,9,9-trimethylspiro[4.5]dec-2-en-10-yl)acetate, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-ol, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)formate, (2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (+-)-2,3-dimethylspiro[4.5]dec-2-en-6-yl acetate, (4~{S},5 ~{R},6~{S},11~{S})-4,11-dimethylspiro[5.5]undecan-5-ol, 9,9-dimethylspiro[4.5]dec-2-en-10-one, 2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 1,1´,1´,5-tetramethyl-2´-methylidenespiro[6-oxabicyclo[3.1.0]hexane-3,3´-cyclohexane], 4,9,9-trimethylspiro[4.5] Dec-2-en-10-one, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-one, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-one, 2-but-3-en-2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one, 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2-but-3-en- Mixture of 2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one and 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol and 2,2-dimethyl-1- Mixture with (3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-ol, 1-methoxy-2,6-dimethyl-1-prop-2-enylcyclohexane, 1-(3-methylbut-2-enyl)cyclohex-2-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, A mixture of methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate and methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-ol, 1-(2,6-dimethylcyclohex-3-en-1-yl)-2,2-dimethylpropan-1-ol, 1-(2-methyl-4-tricyclo[5.2.1.0. 1,5 ]decanyl)ethyl acetate, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0 1,5]decanyl)ethyl acetate, 1-((1R,3S,3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)ethanone, 2,3,4-trimethyltricyclo[5.2.1.0^{1,5}]decane-4-carbaldehyde, (2,3,4-trimethyl-4-trimethyl 1-((3aS,6S)-2,3-dimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one oxime, 1,3-dimethyloctahydro-3a,6-methanoindene-1-carbaldehyde oxime, ~{N}-[1-[(1~{R},7~{R})-2,3,4-trimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)methyl acetate 1,5 ]decanyl]ethylidene]hydroxylamine, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethyl acetate, 1-[(1RS,2RS,4SR,7RS)-2,3,4-trimethyltricyclo[5.2.1.0 1. ~]dec-4-yl)ethanone, (E / Z)-1-[(1RS,7RS)-2,3-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone oxime, (E / Z)-1-[(1S,7S)-2,3,4-trimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethanone oxime, (E / Z)-1-((3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethanone oxime, (+-)-1-(3-methyloctahydro-3a,6-methanoinden-1-yl)ethyl acetate, and combinations thereof.

[0018] In one embodiment, at least one olfactory receptor is a geonol olfactory receptor.In one embodiment, the geonol olfactory receptor is selected from the group consisting of OR11A1 olfactory receptor, OR2M3 olfactory receptor, OR1A1 olfactory receptor, OR2W1 olfactory receptor, OR1A1 olfactory receptor, OR2J3 olfactory receptor, OR4Q3 olfactory receptor, and OR5K1 olfactory receptor.

[0019] In one embodiment, the at least one compound that inhibits the geonol olfactory receptor is [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, 1-(2,6,6-trimethyl-1-cyclohex-3-enyl)but-2-en-1-one, 2-tert-butylphenol, 5-methyl-2-(propan-2-yl)phenol, nona-2,6-dienal, 1,1-diethoxy-3,7-dimethylocta-2,6-diene, 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde, 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene; 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, 3-(4-t ert-Butylphenyl)propanal, (4R,4aS,6R)-4,4a-dimethyl-6-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one, geranyl acetate, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-ethoxy-5-prop-1-enylphenol, 2,6,6,8-tetramethyl-9-oxatetracyclo[5.4.1.0^{1,5}.0^{8,10}]dodecane, nonyl aldehydes, isobutylquinoline, cyclopentadec-4-en-1-one, (-)-(R)-3,7-dimethyl-6-octenenitrile, 2-methyl-5-propan-2-ylphenol, isopropylquinolone, 5-hexyl-2-methylpyridine, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 2-pentylcyclopentan-1-one, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl ) but-3-en-2-one; 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, 2,4-dimethylcyclohex-3-enecarbaldehyde, phenylethylol, 3,7-dimethylocta-2,6-dienal, (2,2,2-trichloro-1-phenylethyl)acetate, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one, phenylethyl acetate, 7-hydroxy-3,7-dimethyloctanal, methyl citral, 6,10-dimethylundec-5,9-dien-2-one, 2-ethoxy-5-prop-1-enylphenol, and combinations thereof.

[0020] In one embodiment, at least one olfactory receptor is a 1-octen-3-ol olfactory receptor.In one embodiment, the 1-octen-3-ol olfactory receptor is selected from the group consisting of OR2W1 olfactory receptor, OR1A1 olfactory receptor, OR2J3 olfactory receptor, OR4Q3 olfactory receptor, and OR5K1 olfactory receptor.

[0021] In one embodiment, the at least one compound that inhibits the 1-octen-3-ol olfactory receptor is selected from the group consisting of isobutylquinoline, 2-tertbutylphenol, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, (4-methyl-4-phenylpentan-2-yl)acetate, (+-)-3-methylcyclopentadecanone, 1-(4,8-dimethyl-12-methylidenecyclododeca-4,8-dien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-1,5,9-trien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-2,5,9-trien-1-yl)ethanone, cyclopentadec-4-en-1-one, cyclododecanone, 2,4-dimethylcyclohex-3-enecarbaldehyde, 1,4-dioxacyclohexadecane-5,16-dione, pentanol, oxacyclohexadecan-2-one, 1,1,2,3 ,3-Pentamethyl-2,5,6,7-tetrahydroinden-4-one, (+-)-Perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, 2,3,3-trimethyl-2H-inden-1-one, 4-(4,8-Dimethylnona-3,7-dienyl)pyridine, 4-[(1~{R},3~{R},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one; 4-[(1~{S},3~{S},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one, (+)-(1R,7R)-10,10-dimethyl-tricyclo[7.1.1.0(2,7)]undec-2-en-4-one, (9 E )-Cycloheptadec-9-en-1-one;8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,5,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,4,5,6,7-hexahydro-1~{H}-naphthalene-2-carbaldehyde;2,2-Dimethyl 2,6,6,8-tetramethyltricyclo[5.3.1.0^{1,5}]undecan-9-one, methyl citral, and combinations thereof.

[0022] In one embodiment, at least one olfactory receptor is DMTS olfactory receptor.In one embodiment, DMTS olfactory receptor is selected from the group consisting of OR4S2 olfactory receptor, OR52N5 olfactory receptor, OR2L13 olfactory receptor, OR2AJ1 olfactory receptor, OR4C15 olfactory receptor, OR5AC2 olfactory receptor, OR8H3 olfactory receptor, OR11G2 olfactory receptor, OR52N2 olfactory receptor, OR5T1 olfactory receptor, OR2W1 olfactory receptor, Olfr1193 olfactory receptor, Olfr1093 olfactory receptor, Olfr1097 olfactory receptor, Olfr166 olfactory receptor, Olfr169 olfactory receptor, Olfr738 olfactory receptor, Olfr742 olfactory receptor, Olfr207 olfactory receptor, Olfr665 olfactory receptor, Olfr669 olfactory receptor and Olfr1211 olfactory receptor.

[0023] In one embodiment, the at least one compound that inhibits the DMTS olfactory receptor is selected from the group consisting of (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-3,6,8,8-tetramethyloctahydro-1H-3a,7-methanoazulen-6-ol, nona-2,6-dienal, (+-)-perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, (1RS,2SR,5RS,7RS,8SR)-5-methyltricyclo[6.2.1.0-2,7-]undecan-4-one (A)+(1 RS,2SR,5SR,7RS,8SR)-5-Methyltricyclo[6.2.1.0~2,7~]undecan-4-one (B), 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene; 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, 4,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, (2-methyl-2-indanyl)methyl acetate, 2-pentyl Cyclopentan-1-one, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexanone, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, phenethyl alcohol, diethyl 1,4-cyclohexanedicarboxylate, (+)-(R)-3,7-dimethyl-6-octenal, 3,5,6-trimethyl-3-cyclohexene 3-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde (A) + 4-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde, 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, (4Z ,8 E )-13-oxabicyclo[10.1.0]trideca-4,8-diene, (4E,8E)-4,8-cyclododecadien-1-one (A) + (4E,8Z)-4,8-cyclododecadien-1-one (B) + (4Z,8E)-4,8-cyclododecadien-1-one (C), (1 R ,4 Z ,8 E ,12 R )-13-Oxabicyclo[10.1.0]trideca-4,8-diene;(4 Z ,8 E )-13-Oxabicyclo[10.1.0]trideca-4,8-diene, 2,2,7,7-tetramethyltricyclo[6.2.1.0~1,6~]undecan-6-ol, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2, 3,5,6,7,8~{a}-Hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-Dimethyl-2,3,4,5,6,7-Hexahydro-1~{H}-naphthalene-2-carbaldehyde;2,2-Dimethyl-octahydro-1~{H}-2,4~{a}-methanonaphthalen-8-one;(+)-(1S,2S,3S,5R)-2,6,6-trimethylspiro[bicyclo[3.1 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one; 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one; (5RS,6RS)-2,6,10,10-tetramethyl-1-oxaspiro[4.5]decan-6-ol; (2,2,2-trichloro-1-phenyl)-2,2,2-trimethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,4,5-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,2,2-trimethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetra ... (nylethyl)acetate, patchouli oil, (1S,3S,6R,7R,8S)-2,2,6,8-tetramethyltricyclo[5.3.1.03,8}]undecan-3-ol, (4S,4aS,8aR)-4,8a-dimethyl-1,2,3,4,5,6,7,-octahydronaphthalen-4a-ol, and combinations thereof.

[0024] In one embodiment, at least one olfactory receptor is indole / skatole olfactory receptor.In one embodiment, the indole / skatole olfactory receptor is selected from the group consisting of OR52N2 olfactory receptor, OR11G2 olfactory receptor, OR5AC2 olfactory receptor, OR4C15 olfactory receptor, OR8S1 olfactory receptor, OR11H6 olfactory receptor, OR11H4 olfactory receptor, Olfr665 olfactory receptor, Olfr740 olfactory receptor, Olfr743 olfactory receptor, Olfr746 olfactory receptor, Olfr738 olfactory receptor, Olfr739 olfactory receptor, Olfr741 olfactory receptor, Olfr742 olfactory receptor, Olfr744 olfactory receptor, Olfr748 olfactory receptor and Olfr749 olfactory receptor.

[0025] In one embodiment, the at least one compound that inhibits the indole / skatole olfactory receptor is selected from the group consisting of benzyl formate, (+-)-1-phenylethyl acetate, (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, 3-phenyl-1-propanol, [cis-4-(2-propanyl)cyclohexyl] Methanol, 2-methyl-2-indanmethanol, (2-methyl-2-indanyl)methyl acetate, (+-)-5-ethyl-2-methyl-2-indanmethanol, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 5-methyl-2-indanmethanol, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexyl Xanone, (+-)-2-methoxymethyl-2,5-dimethylindan, 2,5,6-trimethyl-2-indanmethanol, (+-)-(2,4,5-trimethyl-2,3-dihydro-1H-inden-2-yl)methanol, (+-)-2-ethyl-5-methyl-2-indanmethanol, (+-)-2,4-dimethyl-2-indanmethanol, (+-)-2,4,6-trimethyl-2-indanmethanol, (+-)(2,7 -Dimethyl-1,2,3,4-tetrahydro-2-naphthalenyl)methanol, (+-)-(2,6-dimethyl-1,2,3,4-tetrahydro-2-naphthalenyl)methanol, (+-)-(5-methoxy-2-methyl-2,3-dihydro-1H-inden-2-yl)methanol, 2,2-dimethyl-3-phenyl-1-propanol alcohol, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, (+-)-1,2,6-trimethyl-2-indanmethanol, (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxine (isomer A) + (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxine (isomer B) (A+B), 8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1 ~{H}-Naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,5,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,4,5,6,7-hexahydro-1~{H}-naphthalene-2-carbaldehyde;2,2-dimethyl-octahydro-1~{H}-2,4~{a}-methanonaphthalen-8-one,4-t-butylcyclohexanone,1-(2,2-dimethyl-6-methylidenecyclohexyl)pent-1-ene- 3-one;3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one;1-(2,6,6-trimethylcyclohexen-1-yl)pent-1-en-3-one;1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, 2,2-dimethyl-4-phenyl-1,3-dioxolane, (4E,8E)-4,8-cyclododecadien-1-one(A)+(4E,8Z)-4,8-cyclododecadien-1 -one (B) + (4Z,8E)-4,8-cyclododecadien-1-one (C), (+-)-2-((methoxymethoxy)methyl)-2,5-dimethyl-2,3-dihydro-1H-indene, 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde, amyl phenylacetate, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one;4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, 3-phenylbutanal, 2,4-dimethyl-4-phenyloxolane, 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.0.0]; 4,6 ]dodecane, 2-methyl-3-(4-methylphenyl)propanal, 3-methyl-5-phenylpentanal, isopropyl quinolone, (+-)-(2E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 4,5,6,7,8,9,10,11,12,13-decahydrocyclododeca[d][1,3]oxazole, and combinations thereof.

[0026] In one embodiment, the fragrance composition comprises a malodor receptor antagonist system comprising at least one component selected from the group in Table 1, and a non-functional perfume formulation.

[0027] In one embodiment, the fragrance composition comprises: (i) from about 2 wt % to about 85 wt % of a malodor receptor antagonist system comprising at least one component selected from the group in Table 1; (ii) about 15 wt % to 98 wt % of a functional fragrance blend containing at least two fragrance ingredients, preferably a fragrance blend having an odor note selected from floral, citrus, and jasmine, if any ingredient listed in Table 1 is excluded; and (iii) Optionally, non-functional fragrance additives.

[0028] In one embodiment, the fragrance composition is incorporated into a consumer product. [Brief description of the drawings]

[0029] [Figure 1] 1 illustrates certain malodor targets and olfactory receptors according to some embodiments presented herein. [Diagram 2] Compounds according to some embodiments of the present disclosure show the ability to reduce the perceived strength of geonol in human sensory panel tests.Many of these compounds have been shown to inhibit the activity of geonol olfactory receptors.NS indicates that there is no statistical difference in the perceived strength of geonol remaining compared to the same concentration of geonol alone.Asterisk (*) indicates that there is a statistical difference in the perceived strength of geonol remaining compared to the same concentration of geonol alone. [Diagram 3] The ability of compounds according to some embodiments of the present disclosure to reduce the perceived intensity of butyric acid in a human sensory panel test (gray bars) is shown. Pleasantness of compounds delivered alone (triangles, dashed line) and in mixtures with butyric acid at equipotent concentrations (squares, solid line). Many of these compounds have been shown to inhibit the activity of butyric acid olfactory receptors. All compounds showed a statistically significant reduction in malodor compared to 0.04% (equal potency) butyric acid. [Figure 4] The ability of compounds according to some embodiments of the present disclosure to reduce the perceived intensity of trans-pyrrole in a human sensory panel test (gray bars) is shown. Pleasantness of compounds delivered alone (triangles, dashed line) and in mixtures with trans-pyrrole at equipotent concentrations (squares, solid line). Many of these compounds have been shown to inhibit the activity of trans-pyrrole olfactory receptors. All compounds showed a statistically significant reduction in malodor compared to 0.0015% (equal potency) trans-pyrrole. [Diagram 5]The ability of compounds according to some embodiments of the present disclosure to reduce the perceived intensity of HMHA in a human sensory panel test (gray bars). Pleasantness of compounds delivered alone (triangles, dashed line) and in mixtures with HMHA at equipotent concentrations (squares, solid line). Many of these compounds have been shown to inhibit the activity of HMHA olfactory receptors. NS indicates no statistically significant reduction in malodor compared to 2% (equal strength) HMHA. Compounds with * (asterisk) showed statistically significant reduction in malodor compared to 2% (equal strength) HMHA. [Figure 6] FIG. 1 shows the efficacy of various antagonists as inhibitors of the indole / skatole acid olfactory receptor Olfr742 under highly stringent screening conditions. [Figure 7] FIG. 1 shows the efficacy of various antagonists as inhibitors of the indole / skatole acid olfactory receptor Olfr744 under highly stringent screening conditions. [Figure 8] FIG. 1 shows the potency of various antagonists as indole / skatole acid olfactory receptor Olfr749 inhibitors under highly stringent screening conditions. [Figure 9] FIG. 1 shows the potency of various antagonists as inhibitors of the indole / skatole acid olfactory receptor Olfr746 under highly stringent screening conditions.

[0030] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS In the following description, reference is made to certain possible embodiments that are shown by way of example. These embodiments are described in detail to enable those skilled in the art to practice the invention described herein, and it is to be understood that other embodiments may be utilized and logical changes may be made without departing from the scope of the embodiments presented herein. Thus, the following description of exemplary embodiments is not to be taken in a limiting sense, and the scope of the various embodiments presented herein is defined by the appended claims.

[0031] The Abstract is provided to comply with 37 CFR 1.72(b) to allow the reader to immediately ascertain the nature and gist of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.

[0032] Some embodiments provided herein provide a method of inhibiting, reducing, or suppressing the perception of malodor in a subject, comprising contacting the subject with at least one compound in an amount sufficient to inhibit, reduce, or suppress the perception of malodor by the subject. In some embodiments, the malodor is selected from the group consisting of toilet malodor, laundry malodor, mold malodor, and sweat malodor.

[0033] Non-limiting examples of kitchen malodors include any type of malodor present in a residential or commercial kitchen, including, but not limited to, kitchen garbage odors that may result from the disposal of raw or cooked meat, fish, vegetables, fruits, and / or dairy products; odors generated during cooking, particularly odors generated from raw fish, uncooked garlic, and uncooked onions; cooking odors, particularly odors generated when cooking meat, fish, onions, and / or garlic; odors from cooking oils used for frying; burnt odors that may result from overcooking or burning food; odors emanating from a kitchen sink drain; odors emanating from an in-sink garbage disposal; and odors emanating from a refrigerator.

[0034] Non-limiting examples of bathroom or toilet malodors include any type of malodor present in a residential or public bathroom / toilet, including, but not limited to, odors present immediately after using the toilet; lingering toilet odors; stagnant urine odors; and moldy or musty odors that often occur in wet areas of the bathroom, such as around the bathtub or shower.

[0035] Non-limiting examples of tobacco odors include the odor generated during smoking of a cigarette, cigar, or smoking pipe, or the stale smoky odor remaining after use of a tobacco product in a room, or the odor generated from an ashtray containing trash from a cigarette, cigar, or smoking pipe.

[0036] Non-limiting examples of pet odors include any type of odor associated with indoor pets, particularly cats or dogs, including, but not limited to, fecal odor from a litter box; urine odor from a litter box; residual urine odor; wet dog odor; and pet bed odor.

[0037] Non-limiting examples of body odor include any type of odor emitted by the human body, including, but not limited to, axillary (underarm) odor, scalp odor, foot odor, and vaginal odor. "Body odor" also means odor that originates from the human body and is transferred to other materials, such as fabrics, which may include, for example, the odor of socks after wearing, or the odor of sportswear after wearing.

[0038] Non-limiting examples of laundry odors include stains, mildew, and odors present in washing machines, such as those present on mechanics' clothes; food handlers' clothes, especially butchers' and cooks' clothes; sewer workers' clothes; bartenders' clothes; firefighters' clothes; farm clothes; athletic clothes; factory workers' clothes; heavy equipment operators' clothes.

[0039] Without intending to be limited to a particular theory, residential, body, or laundry malodors are typically due to various malodor targets such as indole, skatole, dimethyl trisulfide (DMTS), dimethyl disulfide (DMDS), p-cresol, and methanethiol (present in fecal malodors); piperidine and morpholine (present in urine odors); 1-octen-3-ol, geonol, butyric acid, nonen-1-ol, and borneol (present in laundry or mold malodors), pyridine and triethylamine (present in kitchen and garbage malodors); and short chain fatty acids such as 3-methyl-3-hydroxyhexanoic acid, 3-methylhexanoic acid, 3-2-methyl-2-hexenoic acid, 3-methyl-3-hydroxyhexanoic acid, 3-methyl-2-hexenoic acid, or 3-methyl-3-sulfanylhexanol (transpyrrole) (present in axillary malodors). As used herein, "malodor target" is intended to denote the molecular components of fecal malodor, sweat malodor, or mold malodor, or laundry malodor.

[0040] In some embodiments, the malodor target is butyric acid, which is found in toilet malodors as described by Lin et al, Environ. Sci. Technol., 2013, 47(14), pp7876-7882.

[0041] In some embodiments, the malodor target is butyric acid, which is found in toilet malodors as described by Chappuis et al, Environ. Sci. Technol., 2015, 49(10), pp6134-6140.

[0042] In some embodiments, the malodor target is butyric acid according to toilet malodor as described by Yasuhara, Chemosphere, 1980, 9(9), pp587-592.

[0043] In some embodiments, the malodor target is butyric acid according to body odor as described by Gabbanini et al, Skin Res. & Technol, 2009, 15(4), pp503-510.

[0044] In some embodiments, the malodor target is butyric acid according to body odor as described by Gallager et al, BJ Dermatol., 2008, 159(4), pp780-791.

[0045] In some embodiments, the malodor target is butyric acid according to laundry malodors as described by McQueen et al, J. Textile Inst., 2008, 99(6), pp515-523.

[0046] In some embodiments, the malodor target is butyric acid according to the malodors described in Susya et al, Atmospheric Environment, 2011, 45(6), pp1236-1241.

[0047] In some embodiments, the malodor target is butyric acid according to the oral malodor described by Van den Velds et al, J. Dental Res., 2009, 88(3), pp285-289.

[0048] In some embodiments, the malodor target is selected from the malodor targets described in Munk et al, J. Surf. Deterg. 4 (2001) 385-394.

[0049] In some embodiments, the malodor target is selected from the malodor targets described in Chung et al, Fibers Polym. 13 (2012) 740-747.

[0050] In some embodiments, the malodor target is selected from the malodor targets described in Takeuchi et al, Flav. Fragr. J. 27 (2012) 89-94.

[0051] In some embodiments, the malodor target is selected from the malodor targets described in Nagoh et al, Tenside Surf. Det. 42 (2005) 7-12.

[0052] In some embodiments, the malodor target is selected from the malodor targets described in Stapleton et al, Lett. Appl. Microbiol. 56 (2013) 299-306.

[0053] In some embodiments, the malodor target is selected from the malodor targets described in Stapleton et al, J. Chromatography. A 1295 (2013) 147-151.

[0054] In some embodiments, the malodor contains at least one malodor target selected from the group consisting of indole / skatole, DMTS, butyric acid, 1-octen-3-ol, geonol, nonen-1-ol, and borneol.

[0055] In some embodiments, the malodor target can be butyric acid. Alternatively, the malodor target can be 1-octen-3-ol. Alternatively, the malodor target can be geonol. Alternatively, the malodor target can be nonen-1-ol. Alternatively, the malodor target can be borneol. Alternatively, the malodor target can be indole / skatole. Alternatively, the malodor target can be DMTS.

[0056] Without intending to be limited to a particular theory, at least one compound inhibits, reduces or suppresses the subject's perception of malodor by inhibiting at least one olfactory receptor involved in the subject's perception of malodor.In some embodiments, at least one compound is the antagonist of at least one olfactory receptor.

[0057] As used herein, the term "olfactory receptor involved in the perception of malodour by a subject" refers to an olfactory receptor that is activated by a malodour target.

[0058] As used herein, the term "butyric acid olfactory receptor" refers to an olfactory receptor that is activated by the malodor target butyric acid.

[0059] Non-limiting examples of butyric acid olfactory receptors suitable for inhibition by the compounds of the present disclosure include Olfr558 and OR51E1.

[0060] As used herein, the term "geonol olfactory receptor" refers to an olfactory receptor that is activated by the malodor target geonol. In some embodiments, geonol is (+-)-perhydro-4 alpha, 8A beta-dimethyl-4A naphthalenol.

[0061] Non-limiting examples of geonol olfactory receptors suitable for inhibition by compounds of the present disclosure include OR11A1, OR2M3, OR1A1, OR2W1, OR1A1, OR2J3, OR4Q3, and OR5K1.

[0062] As used herein, the term "geosmin" or "geonol" refers to (4S,4aS,8aR)-4,8a-dimethyl-1,2,3,4,5,6,7,-octahydronaphthalen-4a-ol.

[0063] As used herein, the term "1-octen-3-ol olfactory receptor" refers to an olfactory receptor that is activated by the malodor target 1-octen-3-ol.

[0064] Non-limiting examples of 1-octen-3-ol olfactory receptors suitable for inhibition by compounds of the present disclosure include OR2W1, OR1A1, OR2J3, OR4Q3, and OR5K1.

[0065] As used herein, the term "DMTS" refers to the olfactory receptors activated by DMTS, which are malodor targets.

[0066] Non-limiting examples of DMTS olfactory receptors suitable for inhibition by the compounds of the present disclosure include OR4S2, OR52N5, OR2L13, OR2AJ1, OR4C15, OR5AC2, OR8H3, OR11G2, OR52N2, OR5T1, OR2W1, OR1A1, Olfr1193, Olfr1093, Olfr1097, Olfr166, Olfr169, Olfr738, Olfr742, Olfr207, Olfr665, Olfr669, Olfr1211, Olfr263, and Olfr173.

[0067] As used herein, the term "indole / skatole" refers to olfactory receptors that are activated by the malodor targets indole and / or skatole.

[0068] Non-limiting examples of indole / skatole olfactory receptors suitable for inhibition by the compounds of the present disclosure include OR52N2, OR11G2, OR5AC2, OR4C15, OR8S1, OR11H6, OR11H4, Olfr665, Olfr738, Olfr739, Olfr740, Olfr741, Olfr742, Olfr743, Olfr744, Olfr746, Olfr748, and Olfr749.

[0069] Other examples of olfactory receptors suitable for inhibition by the compounds of the invention include orthologues of the human olfactory receptors described herein. Other examples of olfactory receptors suitable for inhibition by the compounds of the invention include Olfr263, Olfr403, Olfr137, Olfr735, Olfr173, Olfr96, Olfr164, Olfr558, Olfr1193, and Olfr641. Such receptors may have 70-90% amino acid identity with the corresponding human olfactory receptor orthologues.

[0070] As used herein, the terms "antagonist," "inhibitor," "blocker," "suppressor," "neutralizer," and "modulator" of olfactory receptors are used interchangeably to refer to inhibitory, blocking, suppressive, or modulating molecules, e.g., ligands, antagonists, and their homologs and mimetics, identified using in vivo, ex vivo, and in vitro assays for olfactory transduction. Inhibitors are compounds that, e.g., partially or completely block stimulation by binding, reduce, suppress, hinder, delay activation, inactivate, desensitize, or downregulate olfactory transduction, e.g., antagonists. Activators are compounds that, e.g., stimulate, increase, open activity by binding, promote, enhance activation, sensitize, or upregulate olfactory transduction, e.g., agonists. Modulators include, for example, compounds that alter the interaction of receptors with extracellular proteins that bind activators or inhibitors (e.g., odorant-binding protein, ebnerin, and other members of the hydrophobic carrier family); G proteins; kinases (e.g., homologs of rhodopsin kinase and beta-adrenergic receptor kinase, which are involved in receptor inactivation and desensitization); and arrestins (which also inactivate and desensitize receptors).

[0071] The ability of the compounds of the present disclosure to inhibit or antagonize butyric acid olfactory receptors can be determined by any suitable method readily selected by one of skill in the art, such as, for example, by ex vivo cultured neuronal assays or by in vitro assays using cell lines expressing butyric acid olfactory receptors.

[0072] Such assays for inhibitors and activators include, for example, expressing an OR family member in cells or cell membranes and applying a putative modulator compound in the presence or absence of a malodorous molecule (e.g., butyric acid) and then determining the functional effect on olfactory transduction, as described in the Examples below. Samples or assays containing an OR family member treated with a potential inhibitor are compared to a control sample that does not contain the inhibitor to examine the degree of inhibition. The control sample (not treated with inhibitor, but treated with malodorous odor) is set as a relative maximum OR activity value of 100%. Inhibition of an OR is achieved when the normalized OR activity value relative to the control is about 80%, optionally 50% or 25-0%. Alternatively, in some embodiments, inhibition of an OR is measured by measuring the IC of an antagonist compound. 50 Alternatively, in some embodiments, inhibition of an OR is achieved when the IC value of an antagonist compound is less than or equal to 1500 μM. 50 Alternatively, in some embodiments, inhibition of an OR is achieved when the IC value of an antagonist compound is less than or equal to 200 μM. 50 This is achieved when the value is below 20 μM.

[0073] As used herein, the term "olfactory receptor" or "OR" refers to one or more members of the G protein-coupled receptor (GPCR) family that are expressed in olfactory cells. Olfactory receptor cells can also be identified based on morphology or by the expression of proteins that are specifically expressed in olfactory cells. OR family members can act as receptors for odorants and have the ability to induce the olfactory transduction cascade.

[0074] Compounds according to some aspects of the disclosure With reference to FIG. 2 and Example 1, the following compound was shown to be an antagonist of the geonol olfactory receptor: [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, 1-(2,6,6-trimethyl-1-cyclohex-3-enyl)but-2-en-1-one, 2-tert-butylphenol, 5-methyl-2-(propan-2-yl)phenol, nona-2,6-dienal, 1,1-diethoxy-3,7-dimethylocta-2,6-diene, 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde, 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene; 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, 3-( 4-tert-Butylphenyl)propanal, (4R,4aS,6R)-4,4a-dimethyl-6-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one, geranyl acetate, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one; 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one; 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-ethoxy-5-prop-1-enylphenol, 8,9-epoxy-2,6,6,8-tetramethyl-tricyclo[5.3.1.0(1,5)]undecane, nonyl aldehydes, isobutylquinoline, cyclopentadec-4-en-1-one, (-)-(R)-3,7-dimethyl-6-octenenitrile, 2-methyl-5-propan-2-ylphenol, isopropylquinolone, 5-hexyl-2-methylpyridine, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 2-pentylcyclopentan-1-one, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 3-methyl-4-(2,6,6-trimethylcyclohex 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, 2,4-dimethylcyclohex-3-enecarbaldehyde, phenylethylol, 3,7-dimethylocta-2,6-dienal, (2,2,2-trichloro-1-phenylethyl)acetate, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one, phenylethyl acetate, 7-hydroxy-3,7-dimethyloctanal, methyl citral, 6,10-dimethylundec-5,9-dien-2-one, and 2-ethoxy-5-prop-1-enylphenol.

[0075] With reference to Example 2, the following compounds have been shown to be antagonists of the 1-octen-3-ol olfactory receptor: isobutylquinoline, 2-tertbutylphenol, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, (4-methyl-4-phenylpentan-2-yl)acetate, (+-)-3-methylcyclopentadecanone, 1-(4,8-dimethyl-12-methylidenecyclododeca-4,8-dien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-1,5,9-trien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-2,5,9-trien-1-yl)ethanone, cyclopentadec-4-en-1-one, cyclododecanone, 2,4-dimethylcyclohex-3-enecarbaldehyde, 1,4-dioxacyclohexadecane-5,16-dione, pentanol, oxacyclohexadecan-2-one, 1,1,2,3 ,3-Pentamethyl-2,5,6,7-tetrahydroinden-4-one, (+-)-Perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, 2,3,3-trimethyl-2H-inden-1-one, 4-(4,8-Dimethylnona-3,7-dienyl)pyridine, 4-[(1~{R},3~{R},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one; 4-[(1~{S},3~{S},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one, (+)-(1R,7R)-10,10-dimethyl-tricyclo[7.1.1.0(2,7)]undec-2-en-4-one, (9 E )-Cycloheptadec-9-en-1-one; 8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2,3,5,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2,3,4,5,6,7-hexahydro-1~{H}-naphthalene-2-carbaldehyde aldehyde; 2,2-dimethyl-octahydro-1~{H}-2,4~{a}-methanonaphthalen-8-one, 2,4~{a},8,8-tetramethyl-1~{a},2,4,5,6,7-hexahydro-1~{H}-cyclopropa[j]naphthalen-3-one; 2,6,6,8-tetramethyltricyclo[5.3.1.0^{1,5}]undecan-9-one, and methyl citral.

[0076] In some embodiments, the antagonist of the geonol olfactory receptor can also be an antagonist of the 1-octen-3-ol olfactory receptor. Alternatively, the antagonist of the geonol olfactory receptor can inhibit, reduce or suppress the subject's perception of the 1-octen-3-ol malodor target.

[0077] With reference to Example 3, the following compounds have been shown to be antagonists of the butyric acid olfactory receptor: (2~{R})-2,4,10,10-tetramethylspiro[5.5]undec-3-en-11-one; (5~{S})-3,5,10,10-tetramethylspiro[5.5]undec-3-en-11-one, (+-)-3-methylcyclopentadecanone, (3~{R})-3-methylcyclopentadecanone-5-en-1-one, (-)-(3R)-3-methyl-1-cyclopentadecanone, methoxycyclododecane, 1-(4,8-dimethyl-12-methylidenecyclododeca-4,8-dien-1-yl)ethanone; 1-(2,6,10-trimethylcyclododeca-1,5,9-trien-1-yl)ethanone; 1-(2,6,10 -Trimethylcyclododeca-2,5,9-trien-1-yl)ethanone, 1-(2,6,6-trimethylcyclohexen-1-yl)hepta-1,6-dien-3-one;1-(2,6,6-trimethylcyclohex-2-en-1-yl)hepta-1,6-dien-3-one, (+-)-(2E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl )-2-buten-1-one, (2E)-1-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-buten-1-one, 1-(2,6,6-trimethyl-1-cyclohex-3-enyl)but-2-en-1-one, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6 ]dodecane, (4-methyl-4-phenylpentan-2-yl)acetate, and (ethoxymethoxy)cyclododecane.

[0078] Antagonists for the butyric acid olfactory receptor In some embodiments, compounds of the present disclosure have IC50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 is 180-200μM.

[0079] In some embodiments, compounds of the present disclosure have IC 50In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC50 is 4 to 5 μM.

[0080] In some embodiments, compounds of the present disclosure have IC 50 is 4 μM, or 5 μM, or 6 μM, or 7 μM, or 8 μM, or 9 μM, or 10 μM, or 20 μM, or 30 μM, or 40 μM, or 50 μM, or 60 μM, or 70 μM, or 80 μM, or 90 μM, or 100 μM, or 120 μM, or 140 μM, or 160 μM, or 180 μM, or 200 μM.

[0081] In some embodiments, the at least one compound that inhibits the butyric acid olfactory receptor is selected from the group consisting of (1RS,6RS,11RS)-2,2,9,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,2,7,11-tetramethylspiro[5.5]undec-8-en-1-yl-acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-2-en-6-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-6-yl acetate, 1,5,10,10-tetramethylspiro[5. 5]undec-3-en-11-yl acetate, 2,3,9,9-tetramethylspiro[4.5]dec-10-yl)acetate, (5,10,10-trimethylspiro[5.5]undec-2-en-11-yl)formate, (3,5,10,10-tetramethylspiro[5.5]undec-2-en-11-yl)acetate, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (9,9-dimethylspiro[4.5]dec-2-en-10-yl)acetate, 10-methoxy-9,9-dimethylspiro[4.5]dec-2-en-10-yl 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol, 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, mixture of 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol and 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol, 2,9,11-trimethylspiro[5.5]undec-9-en-11-ol, -en-5-ol, a mixture of 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol and 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, 3-methyl-5-propan-2-ylspiro[5.5]undec-2-en-11-ol, 11-methylspiro[5.5]undecane-5-ol, 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 4,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 3,10,10-trimethylspiro[5.5]Undec-3-en-11-ol and 4,10,10-trimethylspiro[5.5]undec-3-en-11-ol mixture, [2,2-dimethyl-1-(2,4,6-trimethylcyclohex-3-en-1-yl)propyl]acetate, [2,2-dimethyl-1-(2,4,6-trimethylcyclohexyl)propyl]acetate, (1RS)-2,2-dimethyl-1-[(1SR,2SR)-2-methylcyclohexyl]propyl acetate, 9,9-dimethylspiro[4.5]dec-2-en-11-ol mixture, 2,3,9,9-Tetramethylspiro[4.5]dec-10-ol, (2,2,3,3,9,9-Hexamethylspiro[4.5]dec-10-yl)acetate, 9-Methoxy-8,8-dimethylspiro[4.4]non-2-ene, (8,8-Dimethylspiro[4.4]non-2-en-9-yl)acetate, 2,3,8,8-Tetramethylspiro[4.4]non-2-en-9-one, 2,3,9,9-Tetramethylspiro[4.5]dec-2-en-10-ol, 4-Methoxy- 3,3-Dimethylspiro[4.4]nonane, (4,9,9-trimethylspiro[4.5]dec-2-en-10-yl)acetate, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-ol, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)formate, (2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (+-)-2,3-dimethylspiro[4.5]dec-2-en-6-yl acetate, (4~{S},5 ~{R},6~{S},11~{S})-4,11-dimethylspiro[5.5]undecan-5-ol, 9,9-dimethylspiro[4.5]dec-2-en-10-one, 2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 1,1´,1´,5-tetramethyl-2´-methylidenespiro[6-oxabicyclo[3.1.0]hexane-3,3´-cyclohexane], 4,9,9-trimethylspiro[4.5] Dec-2-en-10-one, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-one, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-one, 2-but-3-en-2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one, 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2-but-3-en- Mixture of 2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one and 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol and 2,2-dimethyl-1- Mixture with (3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-ol, 1-methoxy-2,6-dimethyl-1-prop-2-enylcyclohexane, 1-(3-methylbut-2-enyl)cyclohex-2-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, A mixture of methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate and methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-ol, 1-(2,6-dimethylcyclohex-3-en-1-yl)-2,2-dimethylpropan-1-ol, 1-(2-methyl-4-tricyclo[5.2.1.0. 1,5 ]decanyl)ethyl acetate, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0 1,5]decanyl)ethyl acetate, 1-((1R,3S,3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)ethanone, 2,3,4-trimethyltricyclo[5.2.1.0^{1,5}]decane-4-carbaldehyde, (2,3,4-trimethyl-4-trimethyl 1-((3aS,6S)-2,3-dimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one oxime, 1,3-dimethyloctahydro-3a,6-methanoindene-1-carbaldehyde oxime, ~{N}-[1-[(1~{R},7~{R})-2,3,4-trimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)methyl acetate 1,5 ]decanyl]ethylidene]hydroxylamine, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethyl acetate, 1-[(1RS,2RS,4SR,7RS)-2,3,4-trimethyltricyclo[5.2.1.0 1. ~]dec-4-yl)ethanone, (E / Z)-1-[(1RS,7RS)-2,3-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone oxime, (E / Z)-1-[(1S,7S)-2,3,4-trimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethanone oxime, (E / Z)-1-((3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethanone oxime, (+-)-1-(3-methyloctahydro-3a,6-methanoinden-1-yl)ethyl acetate, and combinations thereof.

[0082] In some embodiments, the butyric acid olfactory receptor antagonist has the structure: [ka] [In the formula, the subscript m represents 0 or 1; The subscript n represents 1 or 2; The dotted lines represent single or double bonds; R 1 is a hydrogen atom, a methyl group, or R 6 represents a C(=O) group, where R 6 represents a hydrogen atom or a methyl group, an ethyl group, a propyl group, or an isopropyl group; R 2 , R 3 , and R 4 represent, independently of each other, a hydrogen atom or a methyl group; Each R 5 are each independently a hydrogen atom or C 1-3 represents an alkyl or alkenyl group; and The compounds of formula (I) are antagonists of the butyric acid olfactory receptor. The compound has the following stereoisomeric form or mixture thereof:

[0083] For clarity, by "any one of the stereoisomers" or similar expressions, it is intended to mean the ordinary meaning as understood by those skilled in the art, i.e., that the compounds of the present invention may be in the form of pure or mixtures of enantiomers or diastereoisomers.

[0084] For clarity, by "the dotted line represents a carbon-carbon single bond or a carbon-carbon double bond" or similar language, it is intended to have the ordinary meaning understood by those of skill in the art, i.e., that all bonds (solid and dotted) between the carbon atoms connected by said dotted lines are carbon-carbon single or double bonds.

[0085] In some embodiments, R 2 may be a hydrogen atom.

[0086] In some embodiments, R 3 may be a methyl group.

[0087] In some embodiments, R 4may be a methyl group.

[0088] In some embodiments, the index m may be one.

[0089] In some embodiments, the subscript n may be 1.

[0090] In some embodiments, the dotted line may represent a double bond.

[0091] In some embodiments, R 1 is a hydrogen atom or R 6 C(=O) group, where R 6 represents a hydrogen atom or a methyl group.

[0092] In some embodiments, R 1 is R 6 C(=O) group, where R 6 represents a hydrogen atom or a methyl group.

[0093] In some embodiments, R 1 may represent CH3C(=O).

[0094] In some embodiments, each R 5 are each independently a hydrogen atom or C 1-3 It may represent an alkyl group.

[0095] In some embodiments, each R 5 may each independently represent a hydrogen atom or a methyl or ethyl group.

[0096] In some embodiments, each R 5 may each independently represent a hydrogen atom or a methyl group.

[0097] In some embodiments, one or two R 5 represents a methyl group, and the others may represent hydrogen atoms.

[0098] In some embodiments, the butyric acid olfactory receptor antagonist has the structure: [ka] [In the formula, the subscript m represents 0 or 1; The subscript n represents 1 or 2; The dotted lines represent single or double bonds; R 1 and R 2 represent, independently of each other, a hydrogen atom or a methyl group; Each R 3 are each independently a hydrogen atom or C 1-3 represents an alkyl or alkenyl group; and The compounds of formula (II) are antagonists of the butyric acid olfactory receptor. The compound has the following stereoisomeric form or mixture thereof:

[0099] In some embodiments, the butyric acid olfactory receptor antagonist has the structure: [ka] [In the formula, the subscript m represents 0 or 1; R 1 and R 2 represent, independently of each other, a hydrogen atom or a methyl group; Each R 3 are each independently a hydrogen atom or C 1-4 represents an alkyl or alkenyl group; and The compounds of formula (III) are antagonists of the butyric acid olfactory receptor. The compound has the following stereoisomeric form or mixture thereof:

[0100] In some embodiments, the butyric acid olfactory receptor antagonist has the structure: [ka] [In the formula, the subscript m represents 0 or 1; R 1 is a hydrogen atom, a methyl group, or R 6 represents a C(=O) group, where R6 represents a hydrogen atom or a methyl group, an ethyl group, a propyl group, or an isopropyl group; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a methyl group, or C 1-4 represents an alkyl or alkenyl group; Each R 5 are each independently a hydrogen atom or C 1-4 represents an alkyl or alkenyl group; and The compound of formula (IV) is an antagonist of the butyric acid olfactory receptor. The compound has the following stereoisomeric form or mixture thereof:

[0101] In some embodiments, the compound of formula (I) is selected from the compounds disclosed in US Pat. No. 7,256,170.

[0102] In some embodiments, the compound of formula (I) is (1RS,6RS,11RS)-2,2,9,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,2,7,11-tetramethylspiro[5.5]undec-8-en-1-yl-acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-2-en-6-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-6-yl acetate, 1,5,10,10-tetramethylspiro[5.5]undec-3-en ... -11-yl acetate, (5,10,10-trimethylspiro[5.5]undec-2-en-11-yl)formate, (3,5,10,10-tetramethylspiro[5.5]undec-2-en-11-yl)acetate, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (9,9-dimethylspiro[4.5]dec-2-en-10-yl)acetate, 10-methoxy-9,9-dimethylspiro[4.5]dec-2-ene, 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-yl -en-11-ol, 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, mixture of 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol and 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol, 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol ol and 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, 3-methyl-5-propan-2-ylspiro[5.5]undec-2-en-11-ol, 11-methylspiro[5.5]undecan-5-ol, 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 4,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol and 4,10,10-trimethylspiro[5.5] Mixture with undec-3-en-11-ol, [2,2-dimethyl-1-(2,4,6-trimethylcyclohex-3-en-1-yl)propyl]acetate, [2,2-dimethyl-1-(2,4,6-trimethylcyclohexyl)propyl]acetate, (1RS)-2,2-dimethyl-1-[(1SR,2SR)-2-methylcyclohexyl]propyl acetate, 9,9-dimethyls Pyro[4.5]dec-2-en-10-ol, 2,3,9,9-tetramethylspiro[4.5]decan-10-ol, (2,2,3,3,9,9-hexamethylspiro[4.5]decan-10-yl)acetate, 9-methoxy-8,8-dimethylspiro[4.4]non-2-ene, (8,8-dimethylspiro[4.4]non-2-en-9-yl)acetate, 2,3,8,8-tetramethyl Spiro[4.4]non-2-en-9-one, 2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-ol, 4-methoxy-3,3-dimethylspiro[4.4]nonane, (4,9,9-trimethylspiro[4.5]dec-2-en-10-yl)acetate, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-ol, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-ol (2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)formate, (2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (+-)-2,3-dimethylspiro[4.5]dec-2-en-6-ylacetate, and (4~{S},5~{R},6~{S},11~{S})-4,11-dimethylspiro[5.5]undecan-5-ol.

[0103] In some embodiments, the compound of formula (I) is selected from the group consisting of (+-)-2,3,7,7-tetramethylspiro[4.5]dec-2-en-6-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-6-yl acetate, (9,9-dimethylspiro[4.5]dec-2-en-10-yl)acetate, and 10-methoxy-9,9-dimethylspiro[4.5]dec-2-ene.

[0104] In some embodiments, the compound of formula (II) is selected from the group consisting of 9,9-dimethylspiro[4.5]dec-2-en-10-one, 2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 1,1',1',5-tetramethyl-2'-methylidenespiro[6-oxabicyclo[3.1.0]hexane-3,3'-cyclohexane], and 4,9,9-trimethylspiro[4.5]dec-2-en-10-one.

[0105] In some embodiments, the compound of formula (III) is selected from the group consisting of 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-one, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-one, 2-but-3-en-2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one, a mixture of 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-one and 2-but-3-en-2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one, and 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone.

[0106] In some embodiments, the compound of formula (IV) is 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(3-methylcyclohexyl)propan-1-ol, a mixture of 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol and 2,2-dimethyl-1-(3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-ol, 1-methoxy-2,6-dimethyl-1-prop ... 2-enylcyclohexane, methyl 1-(3-methylbut-2-enyl)cyclohex-2-ene-1-carboxylate, methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, a mixture of methyl 1-(3-methylbut-2-enyl)cyclohex-2-ene-1-carboxylate and methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, and 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-ol.

[0107] In some embodiments, the compound of formula (I) has the structure: [ka]

[0108] In some embodiments, the compound of formula (I) has the structure: [ka]

[0109] In some embodiments, the compound of formula (I) has the structure: [ka]

[0110] In some embodiments, the compound of formula (I) has the structure: [ka]

[0111] In some embodiments, the compound of formula (I) has the structure: [ka]

[0112] In some embodiments, the compound of formula (I) has the structure: [ka]

[0113] In some embodiments, the compound of formula (I) has the structure: [ka]

[0114] In some embodiments, the compound of formula (I) has the structure: [ka]

[0115] In some embodiments, the compound of formula (I) has the structure: [ka]

[0116] In some embodiments, the compound of formula (I) has the structure: [ka]

[0117] In some embodiments, the compound of formula (I) has the structure: [ka]

[0118] In some embodiments, the compound of formula (I) has the structure: [ka]

[0119] In some embodiments, the compound of formula (I) has the structure: [ka]

[0120] In some embodiments, the compound of formula (I) has the structure: [ka]

[0121] In some embodiments, the compound of formula (I) has the structure: [ka]

[0122] In some embodiments, the compound of formula (I) has the structure: [ka]

[0123] In some embodiments, the compound of formula (I) has the structure: [ka]

[0124] In some embodiments, the compound of formula (I) has the structure: [ka]

[0125] In some embodiments, the compound of formula (I) has the structure: [ka]

[0126] In some embodiments, the compound of formula (I) has the structure: [ka]

[0127] In some embodiments, the compound of formula (I) has the structure: [ka]

[0128] In some embodiments, the compound of formula (I) has the structure: [ka]

[0129] In some embodiments, the compound of formula (I) has the structure: [ka]

[0130] In some embodiments, the compound of formula (I) has the structure: [ka]

[0131] In some embodiments, the compound of formula (I) has the structure: [ka]

[0132] In some embodiments, the compound of formula (II) has the structure: [ka]

[0133] In some embodiments, the compound of formula (II) has the structure: [ka]

[0134] In some embodiments, the compound of formula (II) has the structure: [ka]

[0135] In some embodiments, the compound of formula (II) has the structure: [ka]

[0136] In some embodiments, the compound of formula (II) has the structure: [ka]

[0137] In some embodiments, the compound of formula (III) has the structure: [ka]

[0138] In some embodiments, the compound of formula (III) has the structure: [ka]

[0139] In some embodiments, the compound of formula (III) has the structure: [ka]

[0140] In some embodiments, the compound of formula (III) has the structure: [ka]

[0141] In some embodiments, the compound of formula (IV) has the structure: [ka]

[0142] In some embodiments, the compound of formula (IV) has the structure: [ka]

[0143] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0144] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0145] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0146] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0147] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0148] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0149] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0150] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0151] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0152] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0153] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0154] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0155] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0156] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0157] In some embodiments, the at least one inhibitor of the butyric acid olfactory receptor is the following compound: [ka]

[0158] In some embodiments, the butyrate receptor antagonist is 1-(2-methyl-4-tricyclo[5.2.1.0 1,5 ]decanyl)ethyl acetate, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0 1,5]decanyl)ethyl acetate, 1-((1R,3S,3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)ethanone, 2,3,4-trimethyltricyclo[5.2.1.0^{1,5}]decane-4-carbaldehyde, (2,3,4-trimethyl-4-trimethyl 1-((3aS,6S)-2,3-dimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one oxime, 1,3-dimethyloctahydro-3a,6-methanoindene-1-carbaldehyde oxime, ~{N}-[1-[(1~{R},7~{R})-2,3,4-trimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)methyl acetate 1,5 ]decanyl]ethylidene]hydroxylamine, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethyl acetate, 1-[(1RS,2RS,4SR,7RS)-2,3,4-trimethyltricyclo[5.2.1.0 1. ~]dec-4-yl)ethanone, (E / Z)-1-[(1RS,7RS)-2,3-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone oxime, (E / Z)-1-[(1S,7S)-2,3,4-trimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethanone oxime, (E / Z)-1-((3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethanone oxime, (+-)-1-(3-methyloctahydro-3a,6-methanoinden-1-yl)ethyl acetate, and mixtures thereof.

[0159] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0160] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0161] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0162] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0163] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0164] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0165] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0166] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0167] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0168] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0169] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0170] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0171] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka]

[0172] In some embodiments, the antagonist of at least one butyrate receptor has the structure: [ka] It is a compound having the formula:

[0173] Antagonist for the geonol olfactory receptor In some embodiments, the compounds of the present disclosure have IC 50In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 is 180-200μM.

[0174] In some embodiments, the compounds of the present disclosure have IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 is 4 to 5 μM.

[0175] In some embodiments, the compounds of the present disclosure have IC 50 is 4 μM, or 5 μM, or 6 μM, or 7 μM, or 8 μM, or 9 μM, or 10 μM, or 20 μM, or 30 μM, or 40 μM, or 50 μM, or 60 μM, or 70 μM, or 80 μM, or 90 μM, or 100 μM, or 120 μM, or 140 μM, or 160 μM, or 180 μM, or 200 μM.

[0176] In some embodiments, the at least one compound that inhibits the geonol olfactory receptor is [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, 1-(2,6,6-trimethyl-1-cyclohex-3-enyl)but-2-en-1-one, 2-tert-butylphenol, 5-methyl-2-(propan-2-yl)phenol, nona-2,6-dienal, 1,1-diethoxy-3,7-dimethylocta-2,6-diene, 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde, 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene; 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, 3-(4-t ert-Butylphenyl)propanal, (4R,4aS,6R)-4,4a-dimethyl-6-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one, geranyl acetate, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-ethoxy-5-prop-1-enylphenol, 2,6,6,8-tetramethyl-9-oxatetracyclo[5.4.1.0^{1,5}.0^{8,10}]dodecane, nonyl aldehydes, isobutylquinoline, cyclopentadec-4-en-1-one, (-)-(R)-3,7-dimethyl-6-octenenitrile, 2-methyl-5-propan-2-ylphenol, isopropylquinolone, 5-hexyl-2-methylpyridine, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 2-pentylcyclopentan-1-one, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl ) but-3-en-2-one; 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, 2,4-dimethylcyclohex-3-enecarbaldehyde, phenylethylol, 3,7-dimethylocta-2,6-dienal, (2,2,2-trichloro-1-phenylethyl)acetate, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one, phenylethyl acetate, 7-hydroxy-3,7-dimethyloctanal, methyl citral, 6,10-dimethylundec-5,9-dien-2-one, 2-ethoxy-5-prop-1-enylphenol, and combinations thereof.

[0177] 1-Octen-3-ol olfactory receptor antagonist In some embodiments, compounds of the present disclosure have IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 is 180-200μM.

[0178] In some embodiments, compounds of the present disclosure have IC 50 In some embodiments, the compounds of the present disclosure have an IC 50In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 is 4 to 5 μM.

[0179] In some embodiments, compounds of the present disclosure have IC 50 is 4 μM, or 5 μM, or 6 μM, or 7 μM, or 8 μM, or 9 μM, or 10 μM, or 20 μM, or 30 μM, or 40 μM, or 50 μM, or 60 μM, or 70 μM, or 80 μM, or 90 μM, or 100 μM, or 120 μM, or 140 μM, or 160 μM, or 180 μM, or 200 μM.

[0180] In some embodiments, the at least one compound that inhibits the 1-octen-3-ol olfactory receptor is selected from the group consisting of isobutylquinoline, 2-tertbutylphenol, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, (4-methyl-4-phenylpentan-2-yl)acetate, (+-)-3-methylcyclopentadecanone, 1-(4,8-dimethyl-12-methylidenecyclododeca-4,8-dien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-1,5,9-trien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-2,5,9-trien-1-yl)ethanone, cyclopentadec-4-en-1-one, cyclododecanone, 2,4-dimethylcyclohex-3-enecarbaldehyde, 1,4-dioxacyclohexadecane-5,16-dione, pentanol, oxacyclohexadecan-2-one, 1,1,2,3 ,3-Pentamethyl-2,5,6,7-tetrahydroinden-4-one, (+-)-Perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, 2,3,3-trimethyl-2H-inden-1-one, 4-(4,8-Dimethylnona-3,7-dienyl)pyridine, 4-[(1~{R},3~{R},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one; 4-[(1~{S},3~{S},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one, (+)-(1R,7R)-10,10-dimethyl-tricyclo[7.1.1.0(2,7)]undec-2-en-4-one, (9 E )-Cycloheptadec-9-en-1-one;8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,5,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,4,5,6,7-hexahydro-1~{H}-naphthalene-2-carbaldehyde;2,2-Dimethyl 2,6,6,8-tetramethyltricyclo[5.3.1.0^{1,5}]undecan-9-one, methyl citral, and combinations thereof.

[0181] DMTS olfactory receptor antagonist In some embodiments, the compounds of the present disclosure have IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC50 is 180-200μM.

[0182] In some embodiments, the compounds of the present disclosure have IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 is 4 to 5 μM.

[0183] In some embodiments, the compounds of the present disclosure have IC 50 is 4 μM, or 5 μM, or 6 μM, or 7 μM, or 8 μM, or 9 μM, or 10 μM, or 20 μM, or 30 μM, or 40 μM, or 50 μM, or 60 μM, or 70 μM, or 80 μM, or 90 μM, or 100 μM, or 120 μM, or 140 μM, or 160 μM, or 180 μM, or 200 μM.

[0184] In some embodiments, the at least one compound that inhibits the DMTS olfactory receptor is selected from the group consisting of (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-3,6,8,8-tetramethyloctahydro-1H-3a,7-methanoazulen-6-ol, nona-2,6-dienal, (+-)-perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, (1RS,2SR,5RS,7RS,8SR)-5-methyltricyclo[6.2.1.0-2,7-]undecane-4-one (A). +(1RS,2SR,5SR,7RS,8SR)-5-Methyltricyclo[6.2.1.0~2,7~]undecan-4-one (B), 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene; 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, 4,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, (2-methyl-2-indanyl)methyl acetate, 2-pentane ethylcyclopentan-1-one, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexanone, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, phenethyl alcohol, diethyl 1,4-cyclohexanedicarboxylate, (+)-(R)-3,7-dimethyl-6-octenal, 3,5,6-trimethyl-3-cyclohex 3-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde (A) + 4-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde, 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, (4Z ,8 E )-13-oxabicyclo[10.1.0]trideca-4,8-diene, (4E,8E)-4,8-cyclododecadien-1-one (A) + (4E,8Z)-4,8-cyclododecadien-1-one (B) + (4Z,8E)-4,8-cyclododecadien-1-one (C), (1 R ,4 Z ,8 E ,12 R )-13-Oxabicyclo[10.1.0]trideca-4,8-diene;(4 Z ,8 E )-13-Oxabicyclo[10.1.0]trideca-4,8-diene, 2,2,7,7-tetramethyltricyclo[6.2.1.0~1,6~]undecan-6-ol, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2, 3,5,6,7,8~{a}-Hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-Dimethyl-2,3,4,5,6,7-Hexahydro-1~{H}-naphthalene-2-carbaldehyde;2,2-Dimethyl-octahydro-1~{H}-2,4~{a}-methanonaphthalen-8-one;(+)-(1S,2S,3S,5R)-2,6,6-trimethylspiro[bicyclo[3.1 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one; 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one; (5RS,6RS)-2,6,10,10-tetramethyl-1-oxaspiro[4.5]decan-6-ol; (2,2,2-trichloro-1-phenyl)-2,2,2-trimethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,4,5-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,2,2-trimethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetra ... (nylethyl)acetate, patchouli oil, (1S,3S,6R,7R,8S)-2,2,6,8-tetramethyltricyclo[5.3.1.03,8}]undecan-3-ol, (4S,4aS,8aR)-4,8a-dimethyl-1,2,3,4,5,6,7,-octahydronaphthalen-4a-ol, and combinations thereof.

[0185] Indole / skatole olfactory receptor antagonists In some embodiments, compounds of the present disclosure have IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 is 180-200μM.

[0186] In some embodiments, compounds of the present disclosure have IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 In some embodiments, the compounds of the present disclosure have an IC 50 is 4 to 5 μM.

[0187] In some embodiments, compounds of the present disclosure have IC 50 is 4 μM, or 5 μM, or 6 μM, or 7 μM, or 8 μM, or 9 μM, or 10 μM, or 20 μM, or 30 μM, or 40 μM, or 50 μM, or 60 μM, or 70 μM, or 80 μM, or 90 μM, or 100 μM, or 120 μM, or 140 μM, or 160 μM, or 180 μM, or 200 μM.

[0188] In some embodiments, the at least one compound that inhibits the indole / skatole olfactory receptor is selected from the group consisting of benzyl formate, (+-)-1-phenylethyl acetate, (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, 3-phenyl-1-propanol, [cis-4-(2-propanyl)cyclohexyl] 2-Methyl-2-indanethanol, (2-Methyl-2-indanyl)methyl acetate, (+-)-5-ethyl-2-methyl-2-indanethanol, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 5-methyl-2-indanethanol, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexyl hexanone, (+-)-2-methoxymethyl-2,5-dimethylindan, 2,5,6-trimethyl-2-indanmethanol, (+-)-(2,4,5-trimethyl-2,3-dihydro-1H-inden-2-yl)methanol, (+-)-2-ethyl-5-methyl-2-indanmethanol, (+-)-2,4-dimethyl-2-indanmethanol, (+-)-2,4,6-trimethyl-2-indanmethanol, (+-)(2, 7-Dimethyl-1,2,3,4-tetrahydro-2-naphthalenyl)methanol, (+-)-(2,6-Dimethyl-1,2,3,4-tetrahydro-2-naphthalenyl)methanol, (+-)-(5-Methoxy-2-methyl-2,3-dihydro-1H-inden-2-yl)methanol, 2,2-Dimethyl-3-phenyl-1-propanol alcohol, 1-(3,3-Dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, (+-)-1,2,6-trimethyl-2-indanmethanol, (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxine (isomer A) + (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxine (isomer B) (A+B), 8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1 ~{H}-Naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,5,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,4,5,6,7-hexahydro-1~{H}-naphthalene-2-carbaldehyde;2,2-dimethyl-octahydro-1~{H}-2,4~{a}-methanonaphthalen-8-one,4-t-butylcyclohexanone,1-(2,2-dimethyl-6-methylidenecyclohexyl)pent-1-ene- 3-one;3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one;1-(2,6,6-trimethylcyclohexen-1-yl)pent-1-en-3-one;1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, 2,2-dimethyl-4-phenyl-1,3-dioxolane, (4E,8E)-4,8-cyclododecadien-1-one(A)+(4E,8Z)-4,8-cyclododecadien-1 -one (B) + (4Z,8E)-4,8-cyclododecadien-1-one (C), (+-)-2-((methoxymethoxy)methyl)-2,5-dimethyl-2,3-dihydro-1H-indene, 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde, amyl phenylacetate, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one;4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, 3-phenylbutanal, 2,4-dimethyl-4-phenyloxolane, 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.0.0]; 4,6 ]dodecane, 2-methyl-3-(4-methylphenyl)propanal, 3-methyl-5-phenylpentanal, isopropyl quinolone, (+-)-(2E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 4,5,6,7,8,9,10,11,12,13-decahydrocyclododeca[d][1,3]oxazole, and combinations thereof.

[0189] In some embodiments, the at least one compound can be modified to extend, change, increase, or enhance the olfactory neutralizer and / or malodor neutralizer benefits provided by the at least one compound.One example of modification can be to use the at least one compound to generate a precursor, i.e., a pro-fragrance molecule.The pro-fragrance in this case can release the at least one compound by chemical reaction (using O2, light, enzyme, water (pH), or temperature as release trigger) during or after application.

[0190] In some embodiments, the pro-fragrance does not provide any olfactory and / or malodor counteractant benefits.

[0191] Examples of methods used to produce the pro-fragrances are described in WO 2013 / 139766.

[0192] In some embodiments, the pro-fragrance may be a β-thiocarbonyl pro-fragrance derivative, including, but not limited to, 3-(dodecylthio)-1-(2,6,6-trimethylcyclohex-3-en-1-yl)butan-1-one (derived from δ-damascone, manufactured by Firmenich SA, also known under the trademark Haloscent® D and similarly referred to herein) or 3-(dodecylthio)-1-(2,6,6-trimethylcyclohex-2-en-1-yl)butan-1-one (derived from α-damascone) or 4-(dodecylthio)-4-(2,6,6-trimethylcyclohex-2-en-1-yl)butan-2-one (derived from ionone, manufactured by Firmenich SA, also known under the trademark Haloscent® I and similarly referred to herein), or mixtures thereof.

[0193] Further examples of β-thiocarbonyl profrance derivatives of formula (I) suitable for use in the present disclosure include the β-thiocarbonyl profrance derivatives disclosed in WO 2013 / 032885.

[0194] Methods according to some aspects of the present disclosure Some embodiments provided herein include a method of inhibiting, reducing, or suppressing the perception of malodor in a subject, comprising administering to a subject a compound selected from the group consisting of (1RS,6RS,11RS)-2,2,9,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,2,7,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-2-en-6-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-6-yl acetate, 1 ,5,10,10-Tetramethylspiro[5.5]undec-3-en-11-yl acetate, 2,3,9,9-Tetramethylspiro[4.5]decane-10-yl)acetate, (5,10,10-trimethylspiro[5.5]undec-2-en-11-yl)formate, (3,5,10,10-Tetramethylspiro[5.5]undec-2-en-11-yl)acetate, (2,3,9,9-Tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (9,9-Dimethylspiro[4.5]dec-2-en-10-yl)acetate 10-Methoxy-9,9-dimethylspiro[4.5]dec-2-ene, 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol, 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, mixture of 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol and 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol, 1-ol, 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, a mixture of 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol and 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, 3-methyl-5-propan-2-ylspiro[5.5]undec-2-en-11-ol, 11-methylspiro[5.5]undecane-5-ol, 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 4,10,10-trimethylspiro[5.5]Undec-3-en-11-ol, mixture of 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol and 4,10,10-trimethylspiro[5.5]undec-3-en-11-ol, [2,2-dimethyl-1-(2,4,6-trimethylcyclohex-3-en-1-yl)propyl]acetate, [2,2-dimethyl-1-(2,4,6-trimethylcyclohexyl)propyl]acetate, (1RS)-2,2-dimethyl-1-[(1SR,2SR)-2-methylcyclohexyl]propyl acetate, 9,9-dimethylspiro[4.5]dec-2-en-10-ol, 2,3,9,9-tetramethylspiro[4.5]decan-10-ol, (2,2,3,3,9,9-hexamethylspiro[4.5]decan-10-yl)acetate, 9-methoxy-8,8-dimethylspiro[4.4]non-2-ene, (8,8-dimethylspiro[4.4]non-2-en-9-yl)acetate, 2,3,8,8-tetramethylspiro[4.4]non-2-en-9-one, 2,3,9,9-tetramethylspiro[4.5]dec- 2-en-10-ol, 4-methoxy-3,3-dimethylspiro[4.4]nonane, (4,9,9-trimethylspiro[4.5]dec-2-en-10-yl)acetate, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-ol, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)formate, (2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (+-)-2,3-dimethylspiro[4.5]dec-2-en-6-yl acetate , (4~{S},5~{R},6~{S},11~{S})-4,11-dimethylspiro[5.5]undecan-5-ol, 9,9-dimethylspiro[4.5]dec-2-en-10-one, 2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 1,1´,1´,5-tetramethyl-2´-methylidenespiro[6-oxabicyclo[3.1.0]hexane-3,3´-cyclohexane], 4,9,9-trimethylspiro[4.5] Dec-2-en-10-one, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-one, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-one, 2-but-3-en-2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one, 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2-but-3-en- Mixture of 2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one and 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol and 2,2-dimethyl-1- Mixture with (3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-ol, 1-methoxy-2,6-dimethyl-1-prop-2-enylcyclohexane, 1-(3-methylbut-2-enyl)cyclohex-2-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, A mixture of methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate and methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-ol, 1-(2,6-dimethylcyclohex-3-en-1-yl)-2,2-dimethylpropan-1-ol, 1-(2-methyl-4-tricyclo[5.2.1.0. 1,5 ]decanyl)ethyl acetate, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0 1,5]decanyl)ethyl acetate, 1-((1R,3S,3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)ethanone, 2,3,4-trimethyltricyclo[5.2.1.0^{1,5}]decane-4-carbaldehyde, (2,3,4-trimethyl-4-trimethyl 1-((3aS,6S)-2,3-dimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one oxime, 1,3-dimethyloctahydro-3a,6-methanoindene-1-carbaldehyde oxime, ~{N}-[1-[(1~{R},7~{R})-2,3,4-trimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)methyl acetate 1,5 ]decanyl]ethylidene]hydroxylamine, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethyl acetate, 1-[(1RS,2RS,4SR,7RS)-2,3,4-trimethyltricyclo[5.2.1.0 1. ~]dec-4-yl)ethanone, (E / Z)-1-[(1RS,7RS)-2,3-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone oxime, (E / Z)-1-[(1S,7S)-2,3,4-trimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethanone oxime, (E / Z)-1-((3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethanone oxime, (+-)-1-(3-methyloctahydro-3a,6-methanoinden-1-yl)ethyl acetate, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, 1-2,6,6-trimethyl-3-cyclohexen-1-yl-2-buten-1-one, 2-tert-butylphenol, 5-methyl-2-(propan-2-yl)phenol, nona-2,6-dienal, 1,1-diethoxy-3,7-dimethylocta-2,6-diene, 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde, 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene; 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, 3-(4-te rt-Butylphenyl)propanal, (4R,4aS,6R)-4,4a-dimethyl-6-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one, geranyl acetate, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-ethoxy-5-prop-1-enylphenol, 2,6,6,8-tetramethyl-9-oxatetracyclo[5.4.1.0^{1,5}.0^{8,10}]dodecane, nonyl aldehydes, isobutylquinoline, cyclopentadec-4-en-1-one, (-)-(R)-3,7-dimethyl-6-octenenitrile, 2-methyl-5-propan-2-ylphenol, isopropylquinolone, 5-hexyl-2-methylpyridine, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 2-pentylcyclopentan-1-one, 4-(2,6,6-trimethylcyclopentan-1-one, 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one; 2,4-dimethylcyclohex-3-enecarbaldehyde; phenylethylol;. 3,7-Dimethylocta-2,6-dienal, (2,2,2-trichloro-1-phenylethyl)acetate, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one, phenylethyl acetate, 7-hydroxy-3,7-dimethyloctanal, methyl citral, 6,10-dimethylundeca-5,9-dien-2-one, 2-ethoxy-5-prop-1-enylphenol, (4-methyl-4 -phenylpentan-2-yl)acetate, (+-)-3-methylcyclopentadecanone, 1-(4,8-dimethyl-12-methylidenecyclododeca-4,8-dien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-1,5,9-trien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-2,5,9-trien-1-yl)ethanone, cyclododecanone, (Z)-3,4,5, 6,6-Pentamethylhept-3-en-2-one, 1,4-Dioxacyclohexadecane-5,16-dione, Pentanol, Oxacyclohexadecane-2-one, 1,1,2,3,3-Pentamethyl-2,5,6,7-tetrahydroinden-4-one, (+-)-Perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, 2,3,3-Trimethyl-2H-inden-1-one, 4-(4,8-Dimethyl) Nona-3,7-dienyl)pyridine, 4-[(1~{R},3~{R},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one; 4-[(1~{S},3~{S},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one, (+)-(1R,7R)-10,10-dimethyl-tricyclo[7.1.1.0(2,7)]undec-2-en-4-one, (9 E)-Cycloheptadec-9-en-1-one; 8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2,3,5,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2,3,4,5,6,7-hexahydro-1~ {H}-Naphthalene-2-carbaldehyde;2,2-dimethyl-octahydro-1~{H}-2,4~{a}-methanonaphthalen-8-one;2,4~{a},8,8-tetramethyl-1~{a},2,4,5,6,7-hexahydro-1~{H}-cyclopropa[j]naphthalen-3-one;2,6,6,8-tetramethyltricyclo[5.3.1.0 1,5 ]undecane-9-one, (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-3,6,8,8-tetramethyloctahydro-1H-3a,7-methanoazulen-6-ol, (1RS,2SR,5RS,7RS,8SR)-5-methyltricyclo[6.2.1.0~2,7~]undecane -4-one (A) + (1RS,2SR,5SR,7RS,8SR)-5-methyltricyclo[6.2.1.0~2,7~]undecan-4-one (B), ethyl 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, ethyl 4,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, (2-methyl-2-indanyl)methylacetate Tart, 2-pentylcyclopentan-1-one, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexanone, phenethyl alcohol, diethyl 1,4-cyclohexanedicarboxylate, (+)-(R)-3,7-dimethyl-6-octenal, 3,5,6-trimethyl-3-cyclohexene-1-carbaldehyde (A) + 2,4,6-trimethyl-3-cyclohexene-1-carbaldehyde (B), 3,7-dimethylocta-2,6-dienal, 3-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde (A) + 4-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde, (4 Z ,8E )-13-Oxabicyclo[10.1.0]trideca-4,8-diene, (4E,8E)-4,8-cyclododecadien-1-one (A) + (4E,8Z)-4,8-cyclododecadien-1-one (B) + (4Z,8E)-4,8-cyclododecadien-1-one (C), 13-Oxabicyclo[10.1.0]trideca-4,8-diene, 2,2,7,7-tetramethyltricyclo[6.2.1.0~1,6~]undecan-6-ol, (+)-(1S,2S ,3S,5R)-2,6,6-trimethylspiro[bicyclo[3.1.1]heptane-3,1´-cyclohexane]-2´-en-4´-one, (5RS,6RS)-2,6,10,10-tetramethyl-1-oxaspiro[4.5]decan-6-ol, (2,2,2-trichloro-1-phenylethyl)acetate, patchouli oil, (1~{S},3~{S},6~{R},7~{R},8~{S})-2,2,6,8-tetramethyltricyclo[5.3.1.0 3,8]undecan-3-ol, (4S,4aS,8aR)-4,8a-dimethyl-1,2,3,4,5,6,7,-octahydronaphthalen-4a-ol, benzyl formate, (+-)-1-phenylethyl acetate, 3-phenyl-1-propanol, [cis-4-(2-propanyl)cyclohexyl]methanol, 2-methyl-2-indanmethanol, (2-methyl-2-indanyl)methyl acetate, (+-)-5-ethyl-2-methyl-2-indanmethanol, 5-methyl-2 -indanmethanol, (+-)-2-methoxymethyl-2,5-dimethylindan, 2,5,6-trimethyl-2-indanmethanol, (+-)-(2,4,5-trimethyl-2,3-dihydro-1H-inden-2-yl)methanol, (+-)-2-ethyl-5-methyl-2-indanmethanol, (+-)-2,4-dimethyl-2-indanmethanol, (+-)-2,4,6-trimethyl-2-indanmethanol, (+-)(2,7-dimethyl-1,2,3,4-tetrahydro- (+-)-(2,6-dimethyl-1,2,3,4-tetrahydro-2-naphthalenyl)methanol, (+-)-(5-methoxy-2-methyl-2,3-dihydro-1H-inden-2-yl)methanol, 2,2-dimethyl-3-phenyl-1-propanol alcohol, (+-)-1,2,6-trimethyl-2-indanethanol, (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxy (isomer A) + (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxine (isomer B) (A+B), 4-t-butylcyclohexanone, 1-(2,2-dimethyl-6-methylidenecyclohexyl)pent-1-en-3-one; 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohexen-1-yl)pent-1-en-3-one;1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, 2,2-dimethyl-4-phenyl-1,3-dioxolane, (+-)-2-((methoxymethoxy)methyl)-2,5-dimethyl-2,3-dihydro-1H-indene, amyl phenylacetate, 3-phenylbutanal, 2,4-dimethyl-4-phenyloxolane, 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-methyl-3-(4-methylphenyl)propanal, 3-methyl-5-phenylpentanol contacting the subject with at least one compound selected from the group consisting of tanal, (+-)-(2E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 4,5,6,7,8,9,10,11,12,13-decahydrocyclododeca[d][1,3]oxazole, and combinations thereof; Methods are provided in which at least one compound is contacted in an amount sufficient to inhibit, reduce, or suppress the perception of malodor by a subject.

[0195] In some embodiments, the object is contacted with at least one compound by treating a surface or by dispensing at least partially into the air.

[0196] In some embodiments, an amount sufficient to reduce, impede, or inhibit the perception of malodor by a subject is between 10 and 100 ppm.

[0197] In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 20 and 100 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 30 and 100 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 40 and 100 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 50 and 100 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 60 and 100 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 70 and 100 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 80 and 100 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 90 and 100 ppm.

[0198] In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 10 and 90 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 10 and 80 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 10 and 70 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 10 and 60 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 10 and 50 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 10 and 40 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 10 and 30 ppm. In some embodiments, the amount sufficient to reduce, hinder, or inhibit the perception of a malodor by a subject is between 10 and 20 ppm.

[0199] In some embodiments, the contacting inhibits at least one olfactory receptor in the subject.

[0200] In some embodiments, the at least one olfactory receptor is a butyric acid olfactory receptor.

[0201] In some embodiments, the at least one olfactory receptor is a geonol olfactory receptor.

[0202] In some embodiments, the at least one olfactory receptor is a 1-octen-3-ol olfactory receptor.

[0203] In some embodiments, the at least one olfactory receptor is an indole / skatole olfactory receptor.

[0204] In some embodiments, the at least one olfactory receptor is a DMTS olfactory receptor.

[0205] In some embodiments, the amount of at least one compound that is effective in inhibiting the activity of a malodor olfactory receptor is determined by an IC 50 In some embodiments, the amount of at least one compound effective for inhibiting the activity of the malodor olfactory receptor is in the range of 10 to 100 ppm in solution.

[0206] Some embodiments provided herein include a method of inhibiting, reducing, or suppressing the perception of malodor in a subject, comprising administering to a subject a compound selected from the group consisting of (1RS,6RS,11RS)-2,2,9,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,2,7,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-2-en-6-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-6-yl acetate, 1 ,5,10,10-Tetramethylspiro[5.5]undec-3-en-11-yl acetate, 2,3,9,9-Tetramethylspiro[4.5]decane-10-yl)acetate, (5,10,10-trimethylspiro[5.5]undec-2-en-11-yl)formate, (3,5,10,10-Tetramethylspiro[5.5]undec-2-en-11-yl)acetate, (2,3,9,9-Tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (9,9-Dimethylspiro[4.5]dec-2-en-10-yl)acetate 10-Methoxy-9,9-dimethylspiro[4.5]dec-2-ene, 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol, 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, mixture of 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol and 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol, 1-ol, 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, a mixture of 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol and 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, 3-methyl-5-propan-2-ylspiro[5.5]undec-2-en-11-ol, 11-methylspiro[5.5]undecane-5-ol, 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 4,10,10-trimethylspiro[5.5]Undec-3-en-11-ol, mixture of 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol and 4,10,10-trimethylspiro[5.5]undec-3-en-11-ol, [2,2-dimethyl-1-(2,4,6-trimethylcyclohex-3-en-1-yl)propyl]acetate, [2,2-dimethyl-1-(2,4,6-trimethylcyclohexyl)propyl]acetate, (1RS)-2,2-dimethyl-1-[(1SR,2SR)-2-methylcyclohexyl]propyl acetate, 9,9-dimethylspiro[4.5]dec-2-en-10-ol, 2,3,9,9-tetramethylspiro[4.5]decan-10-ol, (2,2,3,3,9,9-hexamethylspiro[4.5]decan-10-yl)acetate, 9-methoxy-8,8-dimethylspiro[4.4]non-2-ene, (8,8-dimethylspiro[4.4]non-2-en-9-yl)acetate, 2,3,8,8-tetramethylspiro[4.4]non-2-en-9-one, 2,3,9,9-tetramethylspiro[4.5]dec- 2-en-10-ol, 4-methoxy-3,3-dimethylspiro[4.4]nonane, (4,9,9-trimethylspiro[4.5]dec-2-en-10-yl)acetate, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-ol, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)formate, (2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (+-)-2,3-dimethylspiro[4.5]dec-2-en-6-yl acetate , (4~{S},5~{R},6~{S},11~{S})-4,11-dimethylspiro[5.5]undecan-5-ol, 9,9-dimethylspiro[4.5]dec-2-en-10-one, 2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 1,1´,1´,5-tetramethyl-2´-methylidenespiro[6-oxabicyclo[3.1.0]hexane-3,3´-cyclohexane], 4,9,9-trimethylspiro[4.5] Dec-2-en-10-one, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-one, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-one, 2-but-3-en-2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one, 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2-but-3-en- Mixture of 2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one and 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol and 2,2-dimethyl-1- Mixture with (3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-ol, 1-methoxy-2,6-dimethyl-1-prop-2-enylcyclohexane, 1-(3-methylbut-2-enyl)cyclohex-2-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, A mixture of methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate and methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-ol, 1-(2,6-dimethylcyclohex-3-en-1-yl)-2,2-dimethylpropan-1-ol, 1-(2-methyl-4-tricyclo[5.2.1.0. 1,5 ]decanyl)ethyl acetate, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0 1,5]decanyl)ethyl acetate, 1-((1R,3S,3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)ethanone, 2,3,4-trimethyltricyclo[5.2.1.0^{1,5}]decane-4-carbaldehyde, (2,3,4-trimethyl-4-trimethyl 1-((3aS,6S)-2,3-dimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one oxime, 1,3-dimethyloctahydro-3a,6-methanoindene-1-carbaldehyde oxime, ~{N}-[1-[(1~{R},7~{R})-2,3,4-trimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)methyl acetate 1,5 ]decanyl]ethylidene]hydroxylamine, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethyl acetate, 1-[(1RS,2RS,4SR,7RS)-2,3,4-trimethyltricyclo[5.2.1.0 1. ~]dec-4-yl)ethanone, (E / Z)-1-[(1RS,7RS)-2,3-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone oxime, (E / Z)-1-[(1S,7S)-2,3,4-trimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethanone oxime, (E / Z)-1-((3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethanone oxime, (+-)-1-(3-methyloctahydro-3a,6-methanoinden-1-yl)ethyl acetate, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, 1-2,6,6-trimethyl-3-cyclohexen-1-yl-2-buten-1-one, 2-tert-butylphenol, 5-methyl-2-(propan-2-yl)phenol, nona-2,6-dienal, 1,1-diethoxy-3,7-dimethylocta-2,6-diene, 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde, 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene; 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, 3-(4-te rt-Butylphenyl)propanal, (4R,4aS,6R)-4,4a-dimethyl-6-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one, geranyl acetate, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-ethoxy-5-prop-1-enylphenol, 2,6,6,8-tetramethyl-9-oxatetracyclo[5.4.1.0^{1,5}.0^{8,10}]dodecane, nonyl aldehydes, isobutylquinoline, cyclopentadec-4-en-1-one, (-)-(R)-3,7-dimethyl-6-octenenitrile, 2-methyl-5-propan-2-ylphenol, isopropylquinolone, 5-hexyl-2-methylpyridine, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 2-pentylcyclopentan-1-one, 4-(2,6,6-trimethylcyclopentan-1-one, 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one; 2,4-dimethylcyclohex-3-enecarbaldehyde; phenylethylol;. 3,7-Dimethylocta-2,6-dienal, (2,2,2-trichloro-1-phenylethyl)acetate, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one, phenylethyl acetate, 7-hydroxy-3,7-dimethyloctanal, methyl citral, 6,10-dimethylundeca-5,9-dien-2-one, 2-ethoxy-5-prop-1-enylphenol, (4-methyl-4 -phenylpentan-2-yl)acetate, (+-)-3-methylcyclopentadecanone, 1-(4,8-dimethyl-12-methylidenecyclododeca-4,8-dien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-1,5,9-trien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-2,5,9-trien-1-yl)ethanone, cyclododecanone, (Z)-3,4,5, 6,6-Pentamethylhept-3-en-2-one, 1,4-Dioxacyclohexadecane-5,16-dione, Pentanol, Oxacyclohexadecane-2-one, 1,1,2,3,3-Pentamethyl-2,5,6,7-tetrahydroinden-4-one, (+-)-Perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, 2,3,3-Trimethyl-2H-inden-1-one, 4-(4,8-Dimethyl) Nona-3,7-dienyl)pyridine, 4-[(1~{R},3~{R},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one; 4-[(1~{S},3~{S},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one, (+)-(1R,7R)-10,10-dimethyl-tricyclo[7.1.1.0(2,7)]undec-2-en-4-one, (9 E)-Cycloheptadec-9-en-1-one; 8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2,3,5,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2,3,4,5,6,7-hexahydro-1~ {H}-Naphthalene-2-carbaldehyde;2,2-dimethyl-octahydro-1~{H}-2,4~{a}-methanonaphthalen-8-one;2,4~{a},8,8-tetramethyl-1~{a},2,4,5,6,7-hexahydro-1~{H}-cyclopropa[j]naphthalen-3-one;2,6,6,8-tetramethyltricyclo[5.3.1.0 1,5 ]undecane-9-one, (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-3,6,8,8-tetramethyloctahydro-1H-3a,7-methanoazulen-6-ol, (1RS,2SR,5RS,7RS,8SR)-5-methyltricyclo[6.2.1.0~2,7~]undecane -4-one (A) + (1RS,2SR,5SR,7RS,8SR)-5-methyltricyclo[6.2.1.0~2,7~]undecan-4-one (B), ethyl 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, ethyl 4,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, (2-methyl-2-indanyl)methylacetate Tart, 2-pentylcyclopentan-1-one, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexanone, phenethyl alcohol, diethyl 1,4-cyclohexanedicarboxylate, (+)-(R)-3,7-dimethyl-6-octenal, 3,5,6-trimethyl-3-cyclohexene-1-carbaldehyde (A) + 2,4,6-trimethyl-3-cyclohexene-1-carbaldehyde (B), 3,7-dimethylocta-2,6-dienal, 3-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde (A) + 4-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde, (4 Z ,8E )-13-Oxabicyclo[10.1.0]trideca-4,8-diene, (4E,8E)-4,8-cyclododecadien-1-one (A) + (4E,8Z)-4,8-cyclododecadien-1-one (B) + (4Z,8E)-4,8-cyclododecadien-1-one (C), 13-Oxabicyclo[10.1.0]trideca-4,8-diene, 2,2,7,7-tetramethyltricyclo[6.2.1.0~1,6~]undecan-6-ol, (+)-(1S,2S ,3S,5R)-2,6,6-trimethylspiro[bicyclo[3.1.1]heptane-3,1´-cyclohexane]-2´-en-4´-one, (5RS,6RS)-2,6,10,10-tetramethyl-1-oxaspiro[4.5]decan-6-ol, (2,2,2-trichloro-1-phenylethyl)acetate, patchouli oil, (1~{S},3~{S},6~{R},7~{R},8~{S})-2,2,6,8-tetramethyltricyclo[5.3.1.0 3,8]undecan-3-ol, (4S,4aS,8aR)-4,8a-dimethyl-1,2,3,4,5,6,7,-octahydronaphthalen-4a-ol, benzyl formate, (+-)-1-phenylethyl acetate, 3-phenyl-1-propanol, [cis-4-(2-propanyl)cyclohexyl]methanol, 2-methyl-2-indanmethanol, (2-methyl-2-indanyl)methyl acetate, (+-)-5-ethyl-2-methyl-2-indanmethanol, 5-methyl-2 -indanmethanol, (+-)-2-methoxymethyl-2,5-dimethylindan, 2,5,6-trimethyl-2-indanmethanol, (+-)-(2,4,5-trimethyl-2,3-dihydro-1H-inden-2-yl)methanol, (+-)-2-ethyl-5-methyl-2-indanmethanol, (+-)-2,4-dimethyl-2-indanmethanol, (+-)-2,4,6-trimethyl-2-indanmethanol, (+-)(2,7-dimethyl-1,2,3,4-tetrahydro- (+-)-(2,6-dimethyl-1,2,3,4-tetrahydro-2-naphthalenyl)methanol, (+-)-(5-methoxy-2-methyl-2,3-dihydro-1H-inden-2-yl)methanol, 2,2-dimethyl-3-phenyl-1-propanol alcohol, (+-)-1,2,6-trimethyl-2-indanethanol, (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxy (isomer A) + (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxine (isomer B) (A+B), 4-t-butylcyclohexanone, 1-(2,2-dimethyl-6-methylidenecyclohexyl)pent-1-en-3-one; 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohexen-1-yl)pent-1-en-3-one;1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, 2,2-dimethyl-4-phenyl-1,3-dioxolane, (+-)-2-((methoxymethoxy)methyl)-2,5-dimethyl-2,3-dihydro-1H-indene, amyl phenylacetate, 3-phenylbutanal, 2,4-dimethyl-4-phenyloxolane, 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-methyl-3-(4-methylphenyl)propanal, 3-methyl-5-phenylpentanol contacting the subject with at least one compound selected from the group consisting of tanal, (+-)-(2E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 4,5,6,7,8,9,10,11,12,13-decahydrocyclododeca[d][1,3]oxazole, and combinations thereof; At least one olfactory receptor is selected from the group consisting of butyrate olfactory receptor, geonol olfactory receptor, 1-octen-3-ol olfactory receptor, indole / skatole olfactory receptor, and DMTS olfactory receptor; and The method includes contacting at least one compound in an amount sufficient to inhibit at least one olfactory receptor.

[0207] In some embodiments, the at least one olfactory receptor is selected from the group consisting of OR2W1, OR1A1, OR2J3, OR4Q3, OR5K1, OR11A1, OR2M3, OR51E1, OR4S2, OR51I2, OR2H1, OR2W3, OR8G1, and the corresponding mouse orthologues Olfr263, Olfr403, Olfr735, Olfr96, Olfr1193, Olfr641, Olfr137, Olfr173, Olfr164, and Olfr558, and mouse ORs Olfr1487, Olfr339, Olfr1126, Olfr93, Olfr398, Olfr120, Olfr1364, Olfr937, Olfr1322, and Olfr46.

[0208] In some embodiments, inhibition of at least one olfactory receptor inhibits, reduces or prevents the perception of malodors in a subject.

[0209] In some embodiments, the malodor is selected from the group consisting of toilet malodor, laundry malodor, mold malodor, and sweat malodor.

[0210] In some embodiments, at least one olfactory receptor is a butyric acid olfactory receptor. In some embodiments, the butyric acid olfactory receptor is selected from the group consisting of OR51E1 olfactory receptor and Olfr558 olfactory receptor.

[0211] In some embodiments, the at least one compound that inhibits the butyric acid olfactory receptor is selected from the group consisting of (1RS,6RS,11RS)-2,2,9,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, (+-)-2,2,7,11-tetramethylspiro[5.5]undec-8-en-1-yl-acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-2-en-6-yl acetate, (+-)-2,3,7,7-tetramethylspiro[4.5]dec-6-yl acetate, 1,5,10,10-tetramethylspiro[5. 5]undec-3-en-11-yl acetate, 2,3,9,9-tetramethylspiro[4.5]dec-10-yl)acetate, (5,10,10-trimethylspiro[5.5]undec-2-en-11-yl)formate, (3,5,10,10-tetramethylspiro[5.5]undec-2-en-11-yl)acetate, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (9,9-dimethylspiro[4.5]dec-2-en-10-yl)acetate, 10-methoxy-9,9-dimethylspiro[4.5]dec-2-en-10-yl 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol, 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, mixture of 4,10,10,11-tetramethylspiro[5.5]undec-2-en-11-ol and 5,10,10,11-tetramethylspiro[5.5]undec-3-en-11-ol, 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol, 2,9,11-trimethylspiro[5.5]undec-9-en-11-ol, -en-5-ol, a mixture of 2,4,8-trimethylspiro[5.5]undec-3-en-11-ol and 2,9,11-trimethylspiro[5.5]undec-9-en-5-ol, 3-methyl-5-propan-2-ylspiro[5.5]undec-2-en-11-ol, 11-methylspiro[5.5]undecane-5-ol, 3,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 4,10,10-trimethylspiro[5.5]undec-3-en-11-ol, 3,10,10-trimethylspiro[5.5]Undec-3-en-11-ol and 4,10,10-trimethylspiro[5.5]undec-3-en-11-ol mixture, [2,2-dimethyl-1-(2,4,6-trimethylcyclohex-3-en-1-yl)propyl]acetate, [2,2-dimethyl-1-(2,4,6-trimethylcyclohexyl)propyl]acetate, (1RS)-2,2-dimethyl-1-[(1SR,2SR)-2-methylcyclohexyl]propyl acetate, 9,9-dimethylspiro[4.5]dec-2-en-11-ol mixture, 2,3,9,9-Tetramethylspiro[4.5]dec-10-ol, (2,2,3,3,9,9-Hexamethylspiro[4.5]dec-10-yl)acetate, 9-Methoxy-8,8-dimethylspiro[4.4]non-2-ene, (8,8-Dimethylspiro[4.4]non-2-en-9-yl)acetate, 2,3,8,8-Tetramethylspiro[4.4]non-2-en-9-one, 2,3,9,9-Tetramethylspiro[4.5]dec-2-en-10-ol, 4-Methoxy- 3,3-Dimethylspiro[4.4]nonane, (4,9,9-trimethylspiro[4.5]dec-2-en-10-yl)acetate, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-ol, (2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)formate, (2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-yl)acetate, (+-)-2,3-dimethylspiro[4.5]dec-2-en-6-yl acetate, (4~{S},5 ~{R},6~{S},11~{S})-4,11-dimethylspiro[5.5]undecan-5-ol, 9,9-dimethylspiro[4.5]dec-2-en-10-one, 2,3,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 2,4,9,9-tetramethylspiro[4.5]dec-2-en-10-one, 1,1´,1´,5-tetramethyl-2´-methylidenespiro[6-oxabicyclo[3.1.0]hexane-3,3´-cyclohexane], 4,9,9-trimethylspiro[4.5] Dec-2-en-10-one, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-one, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-one, 2-but-3-en-2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one, 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2-but-3-en- Mixture of 2-yl-6,6-dimethyl-2-prop-2-enylcyclohexan-1-one and 2,2-bis(2-methyl-2-propen-1-yl)cyclohexanone, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-1-(2-methylcyclohexyl)propan-1-ol and 2,2-dimethyl-1- Mixture with (3-methylcyclohexyl)propan-1-ol, 2,2-dimethyl-6,6-bis(2-methylprop-2-enyl)cyclohexan-1-ol, 1-methoxy-2,6-dimethyl-1-prop-2-enylcyclohexane, 1-(3-methylbut-2-enyl)cyclohex-2-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, A mixture of methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate and methyl 1-(3-methylbut-2-enyl)cyclohex-3-ene-1-carboxylate, 2,2-dimethyl-5,5-bis(2-methylprop-2-enyl)cyclopentan-1-ol, 1-(2,6-dimethylcyclohex-3-en-1-yl)-2,2-dimethylpropan-1-ol, 1-(2-methyl-4-tricyclo[5.2.1.0. 1,5 ]decanyl)ethyl acetate, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0 1,5]decanyl)ethyl acetate, 1-((1R,3S,3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one, 1-(2,4-dimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)ethanone, 2,3,4-trimethyltricyclo[5.2.1.0^{1,5}]decane-4-carbaldehyde, (2,3,4-trimethyl-4-trimethyl 1-((3aS,6S)-2,3-dimethyloctahydro-3a,6-methanoinden-1-yl)ethan-1-one oxime, 1,3-dimethyloctahydro-3a,6-methanoindene-1-carbaldehyde oxime, ~{N}-[1-[(1~{R},7~{R})-2,3,4-trimethyl-4-tricyclo[5.2.1.0^{1,5}]decanyl)methyl acetate 1,5 ]decanyl]ethylidene]hydroxylamine, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone, (+-)-1-(2,4-dimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethyl acetate, 1-[(1RS,2RS,4SR,7RS)-2,3,4-trimethyltricyclo[5.2.1.0 1. ~]dec-4-yl)ethanone, (E / Z)-1-[(1RS,7RS)-2,3-dimethyltricyclo[5.2.1.0 1.5 ]dec-4-yl)ethanone oxime, (E / Z)-1-[(1S,7S)-2,3,4-trimethyltricyclo[5.2.1.0~1.5~]dec-4-yl)ethanone oxime, (E / Z)-1-((3aS,6S)-1,2,3-trimethyloctahydro-3a,6-methanoinden-1-yl)ethanone oxime, (+-)-1-(3-methyloctahydro-3a,6-methanoinden-1-yl)ethyl acetate, and combinations thereof.

[0212] In some embodiments, at least one olfactory receptor is a geonol olfactory receptor. In some embodiments, the geonol olfactory receptor is selected from the group consisting of OR11A1 olfactory receptor, OR2M3 olfactory receptor, OR1A1 olfactory receptor, OR2W1 olfactory receptor, OR1A1 olfactory receptor, OR2J3 olfactory receptor, OR4Q3 olfactory receptor, and OR5K1 olfactory receptor.

[0213] In some embodiments, the at least one compound that inhibits the geonol olfactory receptor is [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, 1-(2,6,6-trimethyl-1-cyclohex-3-enyl)but-2-en-1-one, 2-tert-butylphenol, 5-methyl-2-(propan-2-yl)phenol, nona-2,6-dienal, 1,1-diethoxy-3,7-dimethylocta-2,6-diene, 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde, 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene; 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, 3-(4-t ert-Butylphenyl)propanal, (4R,4aS,6R)-4,4a-dimethyl-6-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one, geranyl acetate, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, 2-ethoxy-5-prop-1-enylphenol, 2,6,6,8-tetramethyl-9-oxatetracyclo[5.4.1.0^{1,5}.0^{8,10}]dodecane, nonyl aldehydes, isobutylquinoline, cyclopentadec-4-en-1-one, (-)-(R)-3,7-dimethyl-6-octenenitrile, 2-methyl-5-propan-2-ylphenol, isopropylquinolone, 5-hexyl-2-methylpyridine, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 2-pentylcyclopentan-1-one, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl ) but-3-en-2-one; 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, 2,4-dimethylcyclohex-3-enecarbaldehyde, phenylethylol, 3,7-dimethylocta-2,6-dienal, (2,2,2-trichloro-1-phenylethyl)acetate, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one, phenylethyl acetate, 7-hydroxy-3,7-dimethyloctanal, methyl citral, 6,10-dimethylundec-5,9-dien-2-one, 2-ethoxy-5-prop-1-enylphenol, and combinations thereof.

[0214] In some embodiments, the effective amount of 1-(2,6,6-trimethyl-1-cyclohex-3-enyl)but-2-en-1-one is 0.02-0.2% w / v.

[0215] In some embodiments, the effective amount of 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one is 0.02 to 0.2% w / v.

[0216] In some embodiments, the effective amount of 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one; 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one is 0.03% w / v.

[0217] In some embodiments, the effective amount of isobutylquinoline is 1-10% w / v.

[0218] In some embodiments, the effective amount of methyl citral is 1% w / v.

[0219] In some embodiments, the effective amount of 1,1-diethoxy-3,7-dimethylocta-2,6-diene is 0.005-0.03% w / v.

[0220] In some embodiments, the effective amount of phenylethyl acetate is 0.3% w / v.

[0221] In some embodiments, the effective amount of 2-tertbutylphenol is 0.5% w / v.

[0222] In some embodiments, the effective amount of 2,4-dimethylcyclohex-3-enecarbaldehyde is 0.2% w / v.

[0223] In some embodiments, the effective amount of 6,10-dimethylundeca-5,9-dien-2-one is 5% w / v.

[0224] In some embodiments, the effective amount of 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one is 5% w / v.

[0225] In some embodiments, the effective amount of 3,7-dimethylocta-2,6-dienal is 0.002-0.15% w / v.

[0226] In some embodiments, the effective amount of 7-hydroxy-3,7-dimethyloctanal is 20-100% w / v.

[0227] In some embodiments, the effective amount of 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one is 0.1-1% w / v.

[0228] In some embodiments, the effective amount of (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol is 15% w / v.

[0229] In some embodiments, the effective amount of 2-methyl-5-propan-2-ylphenol is 2% w / v.

[0230] In some embodiments, the effective amount of 2-ethoxy-5-prop-1-enylphenol is 0.5-5% w / v.

[0231] In some embodiments, at least one olfactory receptor is a 1-octen-3-ol olfactory receptor.In some embodiments, the 1-octen-3-ol olfactory receptor is selected from the group consisting of OR2W1 olfactory receptor, OR1A1 olfactory receptor, OR2J3 olfactory receptor, OR4Q3 olfactory receptor, and OR5K1 olfactory receptor.

[0232] In some embodiments, the at least one compound that inhibits the 1-octen-3-ol olfactory receptor is selected from the group consisting of isobutylquinoline, 2-tertbutylphenol, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.2.0.0 4,6]dodecane, (4-methyl-4-phenylpentan-2-yl)acetate, (+-)-3-methylcyclopentadecanone, 1-(4,8-dimethyl-12-methylidenecyclododeca-4,8-dien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-1,5,9-trien-1-yl)ethanone;1-(2,6,10-trimethylcyclododeca-2,5,9-trien-1-yl)ethanone, cyclopentadec-4-en-1-one, cyclododecanone, 2,4-dimethylcyclohex-3-enecarbaldehyde, 1,4-dioxacyclohexadecane-5,16-dione, pentanol, oxacyclohexadecan-2-one, 1,1,2,3 ,3-Pentamethyl-2,5,6,7-tetrahydroinden-4-one, (+-)-Perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, 2,3,3-trimethyl-2H-inden-1-one, 4-(4,8-Dimethylnona-3,7-dienyl)pyridine, 4-[(1~{R},3~{R},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one; 4-[(1~{S},3~{S},6~{R})-2,2,3,6-tetramethylcyclohexyl]but-3-en-2-one, (+)-(1R,7R)-10,10-dimethyl-tricyclo[7.1.1.0(2,7)]undec-2-en-4-one, (9 E )-Cycloheptadec-9-en-1-one;8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,5,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,4,5,6,7-hexahydro-1~{H}-naphthalene-2-carbaldehyde;2,2-Dimethyl 2,6,6,8-tetramethyltricyclo[5.3.1.0^{1,5}]undecan-9-one, methyl citral, and combinations thereof.

[0233] In some embodiments, the effective amount of (2,2,2-trichloro-1-phenylethyl)acetate is 10% w / v.

[0234] In some embodiments, the effective amount of 1,4-dioxacyclohexadecane-5,16-dione is 50% w / v.

[0235] In some embodiments, the effective amount of oxacyclohexadecan-2-one is 50% w / v.

[0236] In some embodiments, the effective amount of methyl citral is 1% w / v.

[0237] In some embodiments, the effective amount of cyclopentadec-4-en-1-one is 0.5-5% w / v.

[0238] In some embodiments, the effective amount of 2,4-dimethylcyclohex-3-enecarbaldehyde is 0.5% w / v.

[0239] In some embodiments, the effective amount of corps rubarb is 1% w / v.

[0240] In some embodiments, the effective amount of 1,1-diethoxy-3,7-dimethylocta-2,6-diene is 0.005-0.03% w / v.

[0241] In some embodiments, the effective amount of 2,3,3-trimethyl-2H-inden-1-one is 0.07-0.7% w / v.

[0242] In some embodiments, the effective amount of 2,4-{a},8,8-tetramethyl-1-{a},2,4,5,6,7-hexahydro-1-{H}-cyclopropa[j]naphthalen-3-one; 2,6,6,8-tetramethyltricyclo[5.3.1.0^{1,5}]undecan-9-one is 2-20% w / v.

[0243] In some embodiments, at least one olfactory receptor is a DMTS olfactory receptor.In one embodiment, the DMTS olfactory receptor is an OR4S2 olfactory receptor, an OR52N5 olfactory receptor, an OR2L13 olfactory receptor, an OR2AJ1 olfactory receptor, an OR4C15 olfactory receptor, an OR5AC2 olfactory receptor, an OR8H3 olfactory receptor, an OR11G2 olfactory receptor, an OR52N2 olfactory receptor, an OR5T1 olfactory receptor, an OR2W1 olfactory receptor, an OR1A1 olfactory receptor, an OR5K1 olfactory receptor, an Olfr1193 ... r1093 olfactory receptor, Olfr1097 olfactory receptor, Olfr166 olfactory receptor, Olfr169 olfactory receptor, Olfr738 olfactory receptor, Olfr173 olfactory receptor, Olfr263 olfactory receptor, Olfr403 olfactory receptor, Olfr742 olfactory receptor, Olfr207 olfactory receptor, Olfr665 olfactory receptor, Olfr669 olfactory receptor, and Olfr1211 olfactory receptor.

[0244] In some embodiments, the at least one compound that inhibits the DMTS olfactory receptor is selected from the group consisting of (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-3,6,8,8-tetramethyloctahydro-1H-3a,7-methanoazulen-6-ol, nona-2,6-dienal, (+-)-perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, (1RS,2SR,5RS,7RS,8SR)-5-methyltricyclo[6.2.1.0-2,7-]undecane-4-one (A). +(1RS,2SR,5SR,7RS,8SR)-5-Methyltricyclo[6.2.1.0~2,7~]undecan-4-one (B), 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene; 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, 4,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, (2-methyl-2-indanyl)methyl acetate, 2-pentane ethylcyclopentan-1-one, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexanone, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, phenethyl alcohol, diethyl 1,4-cyclohexanedicarboxylate, (+)-(R)-3,7-dimethyl-6-octenal, 3,5,6-trimethyl-3-cyclohex 3-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde (A) + 4-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde, 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one; 1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, (4Z ,8 E )-13-oxabicyclo[10.1.0]trideca-4,8-diene, (4E,8E)-4,8-cyclododecadien-1-one (A) + (4E,8Z)-4,8-cyclododecadien-1-one (B) + (4Z,8E)-4,8-cyclododecadien-1-one (C), (1 R ,4 Z ,8 E ,12 R )-13-Oxabicyclo[10.1.0]trideca-4,8-diene;(4 Z ,8 E )-13-Oxabicyclo[10.1.0]trideca-4,8-diene, 2,2,7,7-tetramethyltricyclo[6.2.1.0~1,6~]undecan-6-ol, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde; 8,8-dimethyl-2, 3,5,6,7,8~{a}-Hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-Dimethyl-2,3,4,5,6,7-Hexahydro-1~{H}-naphthalene-2-carbaldehyde;2,2-Dimethyl-octahydro-1~{H}-2,4~{a}-methanonaphthalen-8-one;(+)-(1S,2S,3S,5R)-2,6,6-trimethylspiro[bicyclo[3.1 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one; 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one; (5RS,6RS)-2,6,10,10-tetramethyl-1-oxaspiro[4.5]decan-6-ol; (2,2,2-trichloro-1-phenyl)-2,2,2-trimethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,4,5-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,6,10,10-tetramethyl-1-phenyl-2,2,2-trimethyl-1-phenyl-2,3,4-trimethyl-1-phenyl-2,5,6-trimethyl-1-phenyl-2,6,10,10-tetra ... (nylethyl)acetate, patchouli oil, (1S,3S,6R,7R,8S)-2,2,6,8-tetramethyltricyclo[5.3.1.03,8}]undecan-3-ol, (4S,4aS,8aR)-4,8a-dimethyl-1,2,3,4,5,6,7,-octahydronaphthalen-4a-ol, and combinations thereof.

[0245] In some embodiments, at least one olfactory receptor is indole / skatole olfactory receptor.In one embodiment, the indole / skatole olfactory receptor is selected from the group consisting of OR52N2 olfactory receptor, OR11G2 olfactory receptor, OR5AC2 olfactory receptor, OR4C15 olfactory receptor, OR8S1 olfactory receptor, OR11H6 olfactory receptor, OR11H4 olfactory receptor, Olfr665 olfactory receptor, Olfr740 olfactory receptor, Olfr743 olfactory receptor, and Olfr746 olfactory receptor, Olfr738 olfactory receptor, Olfr739 olfactory receptor, Olfr741 olfactory receptor, Olfr742 olfactory receptor, Olfr744 olfactory receptor, Olfr748 olfactory receptor, and Olfr749 olfactory receptor.

[0246] In some embodiments, the at least one compound that inhibits the indole / skatole olfactory receptor is selected from the group consisting of benzyl formate, (+-)-1-phenylethyl acetate, (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, 3-phenyl-1-propanol, [cis-4-(2-propanyl)cyclohexyl] 2-Methyl-2-indanethanol, (2-Methyl-2-indanyl)methyl acetate, (+-)-5-ethyl-2-methyl-2-indanethanol, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 5-methyl-2-indanethanol, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexyl hexanone, (+-)-2-methoxymethyl-2,5-dimethylindan, 2,5,6-trimethyl-2-indanmethanol, (+-)-(2,4,5-trimethyl-2,3-dihydro-1H-inden-2-yl)methanol, (+-)-2-ethyl-5-methyl-2-indanmethanol, (+-)-2,4-dimethyl-2-indanmethanol, (+-)-2,4,6-trimethyl-2-indanmethanol, (+-)(2, 7-Dimethyl-1,2,3,4-tetrahydro-2-naphthalenyl)methanol, (+-)-(2,6-Dimethyl-1,2,3,4-tetrahydro-2-naphthalenyl)methanol, (+-)-(5-Methoxy-2-methyl-2,3-dihydro-1H-inden-2-yl)methanol, 2,2-Dimethyl-3-phenyl-1-propanol alcohol, 1-(3,3-Dimethylcyclohexen-1-yl)pent-4-en-1-one;1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, (+-)-1,2,6-trimethyl-2-indanmethanol, (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxine (isomer A) + (+-)-2,4-dimethyl-4,4a,5,9b-tetrahydroindeno[1,2-d][1,3]dioxine (isomer B) (A+B), 8,8-dimethyl-2,3,4,6,7,8~{a}-hexahydro-1 ~{H}-Naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,5,6,7,8~{a}-hexahydro-1~{H}-naphthalene-2-carbaldehyde;8,8-dimethyl-2,3,4,5,6,7-hexahydro-1~{H}-naphthalene-2-carbaldehyde;2,2-dimethyl-octahydro-1~{H}-2,4~{a}-methanonaphthalen-8-one,4-t-butylcyclohexanone,1-(2,2-dimethyl-6-methylidenecyclohexyl)pent-1-ene- 3-one;3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one;1-(2,6,6-trimethylcyclohexen-1-yl)pent-1-en-3-one;1-(2,6,6-trimethylcyclohex-2-en-1-yl)pent-1-en-3-one, 2,2-dimethyl-4-phenyl-1,3-dioxolane, (4E,8E)-4,8-cyclododecadien-1-one(A)+(4E,8Z)-4,8-cyclododecadien-1 -one (B) + (4Z,8E)-4,8-cyclododecadien-1-one (C), (+-)-2-((methoxymethoxy)methyl)-2,5-dimethyl-2,3-dihydro-1H-indene, 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde, amyl phenylacetate, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one;4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, 3-phenylbutanal, 2,4-dimethyl-4-phenyloxolane, 1-(5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, [1R-(1R*,4R*,6R*,10S*)]-4,12,12-trimethyl-9-methylene-5-oxatricyclo[8.0.0]; 4,6 ]dodecane, 2-methyl-3-(4-methylphenyl)propanal, 3-methyl-5-phenylpentanal, isopropyl quinolone, (+-)-(2E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one, 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one; 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, 4,5,6,7,8,9,10,11,12,13-decahydrocyclododeca[d][1,3]oxazole, and combinations thereof.

[0247] In some embodiments, the term "contacting" refers to administering a composition comprising at least one compound described herein to a subject, whereby an effective amount of at least one compound is provided to the subject. Administration can be by any method that is easily selected by those skilled in the art. Methods include, but are not limited to, topical administration, inhalation, and the like. Thus, the present disclosure contemplates formulating a composition comprising at least one compound described herein with a suitable carrier to facilitate administration of the composition comprising at least one compound described herein to a subject.

[0248] Alternatively, in some embodiments, the term "contacting" refers to distributing or dispersing a composition comprising at least one compound as described herein into a volume that requires it, and distributing or dispersing provides an effective amount of at least one compound to a subject.Dispersing or distributing at least one compound as described herein can be achieved by any method that is easily selected by those skilled in the art.Examples include, but are not limited to, spraying, nebulizing, evaporating, etc., of a solution containing at least one compound as described herein.

[0249] Thus, the present disclosure contemplates formulating a composition comprising at least one compound described herein with a carrier suitable for facilitating the use of the composition to treat a surface or volume on a subject.

[0250] In some embodiments, the term "contact" refers to contacting the surface of the malodor source with a composition comprising at least one compound as described herein, and the contact causes an effective amount of at least one compound to be attached to the surface. The composition comprising at least one compound as described herein can be contacted with the surface by any method that is easily selected by those skilled in the art. Examples include, but are not limited to, spray, wipe, solution, etc.

[0251] Products and formulations according to some embodiments presented herein In some embodiments, the present disclosure provides a perfumed consumer product comprising at least one compound in an amount sufficient to reduce, impede, or inhibit the perception of malodor by a subject. In some embodiments, the perfumed consumer product is selected from the group consisting of an air freshening product, a home care product, and a laundry care product.

[0252] In some embodiments, the perfumed consumer product comprising an effective amount of at least one compound comprises a formulation selected from the group consisting of aerosol and / or water-based air freshener sprays, wick / lead air fresheners, liquid electric (plug-in) air fresheners, solid supported air fresheners, gel-based air fresheners, membrane-encapsulated air fresheners, bleaching, cleaning, washing powder detergents, liquid all-purpose cleaners, specialty cleaners, and liquid detergents.

[0253] It is understood by those skilled in the art that at least one compound as defined herein may be added to the composition described herein in its pure form or in a solvent.Alternatively, at least one compound may be modified first by entrapment with a trapping material, such as polymer, capsule, microcapsule, nanocapsule, liposome, precursor, film former, absorbent, such as by using carbon or zeolite, cyclic oligosaccharide, and mixtures thereof.Alternatively, at least one compound may be chemically bound to a substance adapted to release the compound upon application of exogenous stimuli, such as light, enzyme, etc.

[0254] Accordingly, some embodiments presented herein provide a composition comprising: a. at least one compound; b. at least one component selected from the group consisting of a fragrance carrier and a fragrance base; and c. optionally at least one flavoring adjuvant.

[0255] As used herein, the term "perfume carrier" refers to a material that is substantially neutral from the standpoint of perfumery, i.e., that does not significantly alter the organoleptic properties of the fragrance ingredients. Perfume carriers may be liquid or solid.

[0256] Non-limiting examples of liquid perfume carriers include emulsifying systems, i.e., systems of solvents and surfactants, or solvents commonly used in perfume manufacturing. A detailed description of the nature and type of solvents commonly used in perfume manufacturing is not exhaustive. However, non-limiting examples of solvents include dipropylene glycol, diethyl phthalate, isopropyl myristate, benzyl benzoate, 2-(2-ethoxyethoxy)-1-ethanol, or ethyl citrate. For compositions that include both perfume carriers and perfume bases, other suitable perfume carriers other than those specified above may also be ethanol, water / ethanol mixtures, limonene or other terpenes, isoparaffins, such as those known under the trade name Isopar (manufacturer: Exxon Chemical), or glycol ethers and glycol ether esters, such as those known under the trade name Dowanol (manufacturer: Dow Chemical Company).

[0257] Non-limiting examples of solid perfume carriers include absorbent gums or polymers, as well as encapsulating materials.Examples of such materials can include monosaccharides, disaccharides, or trisaccharides, natural or modified starches, hydrocolloids, cellulose derivatives, polyvinyl acetates, polyvinyl alcohols, proteins or pectins, or materials cited in reference books such as H.Scherz, Hydrokolloides: Stabilisatoren, Dickungs-und Geliermittel in Lebensmitteln, Band 2 der Schriftenreihe Lebensmittelchemie, Lebensmittelqualitaet, Behr's Verlag GmbH & Co., Hamburg, 1996.Encapsulation is a process well known to those skilled in the art, and can be carried out using techniques such as spray drying, agglomeration, or even extrusion, or techniques consisting of coating encapsulation, including coacervation and complex coacervation techniques.

[0258] As used herein, the term "perfume base" refers to a composition that includes at least one fragrance auxiliary ingredient. A fragrance auxiliary ingredient does not include at least one compound. As used herein, the term "fragrance auxiliary ingredient" refers to a compound that is used in fragrance preparations or compositions to provide a hedonic effect. In other words, such auxiliary ingredients that are considered to be fragrance ingredients must be recognized by those skilled in the art as not only having a scent, but also being able to provide or modify the scent of the composition in a good or pleasant way.

[0259] The nature and type of fragrance auxiliary ingredients present in the base are not guaranteed to be described in further detail herein, and in any case are not exhaustive, and a person skilled in the art can select them based on his general knowledge and according to the intended use or application and the desired organoleptic effect.Generally speaking, these fragrance auxiliary ingredients belong to various chemical classes, such as alcohols, lactones, aldehydes, ketones, esters, ethers, acetates, nitriles, terpenoids, nitrogen- or sulfur-containing heterocyclic compounds and essential oils, and the fragrance auxiliary ingredients can be of natural or synthetic origin.In any case, many of these auxiliary ingredients are listed in reference books such as the book by S.Arctander, Perfume and Flavor Chemicals, 1969, Montclair, New Jersey, USA, or its latest edition, or other works of the same type, and in the abundant patent literature in the perfumery field.It is understood that the auxiliary ingredient can also be a compound known to release various types of fragrance compounds in a controlled manner.

[0260] As used herein, the term "perfume adjuvant" refers to an ingredient capable of imparting additional benefits such as color, extra light fastness, chemical stability, etc. A detailed description of the nature and types of adjuvants commonly used in fragrance bases cannot be exhaustive, but it should be mentioned that the ingredients are well known to those skilled in the art.

[0261] As used herein, the term perfume or perfume oil or perfume blend is used to denote a mixture of fragrance ingredients.

[0262] In some embodiments, the fragrance composition comprises a malodor receptor antagonist system comprising at least one component selected from the group in Table 1, and a non-functional perfume formulation.

[0263] In some embodiments, the fragrance composition comprises: (i) a malodor receptor antagonist system comprising from about 2 wt % to about 85 wt % of at least one component selected from the group in Table 1; (ii) about 15 wt % to 98 wt % of a functional fragrance blend containing at least two fragrance ingredients, preferably a fragrance blend having an odor note selected from floral, citrus, and jasmine, if any ingredient listed in Table 1 is excluded; and (iii) Optionally, non-functional fragrance additives.

[0264] Without intending to be limited to a particular theory, the association of a malodor receptor antagonist system comprising at least one component selected from the group in Table 1 with a functional blended fragrance comprising fragrance components that act on malodors improves the effectiveness of the functional blended fragrance in limiting, reducing or eliminating the perception of malodors.

[0265] As used herein, the term malodor receptor antagonist, malodor antagonist system or malodor antagonist component, also referred to as group I, is intended to refer to one or several compounds, each of which has the ability to block at least one olfactory receptor that responds to malodor target.This ability is determined by measuring the activity of isolated receptor in olfactory nerve or cultured cell line, whose response is induced by receptor as defined in the following examples.

[0266] As used herein, the term functional blended fragrance (also referred to as Group II) is intended to denote a mixture of at least two fragrance ingredients, also referred to as functional fragrance ingredients, which have been determined, for example by sensory measurements, to act on at least one component of malodour.

[0267] As used herein, the term non-functional blended fragrance (also referred to as Group III) is intended to mean a mixture of at least one or at least two fragrance ingredients, referred to as non-functional fragrance ingredients, which do not act as malodor counteractants, i.e. fragrance ingredients that do not belong to Group I or Group II.

[0268] Moreover, by "fragrance ingredient" herein is intended a compound that can be used in a fragrance preparation or composition to impart at least a hedonic effect, in other words, such an ingredient to be considered as a fragrance ingredient must be recognized by those skilled in the perfumery art as not merely having an odor, but also being able to impart or modify the odor of the composition in a pleasant or pleasant way.

[0269] The nature and type of fragrance ingredients are not guaranteed to be described in further detail herein and are in any case not exhaustive, and the skilled artisan can select them based on his general knowledge and depending on the intended use or application and the desired organoleptic effect. In general terms, these fragrance ingredients belong to different chemical classes, such as alcohols, lactones, aldehydes, ketones, esters, ethers, acetates, nitriles, terpenoids, nitrogen- or sulfur-containing heterocyclic compounds and essential oils, and the fragrance co-ingredients may be of natural or synthetic origin.

[0270] In particular, fragrance ingredients commonly used in fragrance formulations include: · Aldehydic components: decanal, dodecanal, 2-methyl-undecanal, 10-undecenal, octanal, and / or nonenal; Aromatic herbal ingredients: eucalyptus oil, camphor, eucalyptol, menthol, and / or alpha-pinene; · Balsam components: coumarin, ethyl vanillin, and / or vanillin; · Citrus Ingredients: Dihydromyrcenol, 3,7-dimethylocta-2,6-dienal, Orange Oil, Linalyl Acetate, (-)-(R)-3,7-Dimethyl-6-Octenenitrile, Orange Terpenes, Limonene, 1-P-Menthen-8-yl Acetate, and / or 1,4(8)-P-Menthadiene; Floral components: Methyl dihydrojasmonate, Linalool, Citronellol, Phenylethanol, 3-(4-tert-butylphenyl)-2-methylpropanal, Hexylcinnamaldehyde, Benzyl acetate, Benzyl salicylate, Tetrahydro-2-isobutyl-4-methyl-4(2H)-pyranol, Beta-ionone, Methyl 2-(methylamino)benzoate, (E)-3-Methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, Hexyl salicylate, 3,7-Dimethyl-1,6-nonadien-3-ol, 3-(4-Isopropylphenyl)-2-methylpropanal, Vergyl acetate, Geraniol, P-Menth-1-en-8-ol, 4-(1,1-Dimethylethyl)-1-cyclohexyl acetate, 1,1-Dimethylethyl Methyl-2-phenylethyl acetate, 4-cyclohexyl-2-methyl-2-butanol, amyl salicylate, high cis methyl dihydrojasmonate, 3-methyl-5-phenyl-1-pentanol, vergyl propionate, geranyl acetate, tetrahydrolinalool, cis-7-P-menthanol, (S)-2-(1,1-dimethylpropoxy)propyl propanoate, 2-methoxynaphthalene, 2,2,2-trichloro-1-phenylethyl acetate, 4 / 3-(4-hydroxy-4-methylpentyl)-3-cyclohexene-1-carbaldehyde, amyl cinnamaldehyde, 4-phenyl-2-butanone, isononyl acetate, 4-(1,1-dimethylethyl)-1-cyclohexyl acetate, vergyl isobutyrate, and / or a mixture of methyl ionone isomers; · Fruity ingredients: gamma undecalactone, 4-decanolide, ethyl 2-methyl-valerate, hexyl acetate, ethyl 2-methylbutyrate, gamma nonalactone, allyl heptanoate, 2-phenoxyethyl isobutyrate, ethyl 2-methyl-1,3-dioxolane-2-acetate, and / or diethyl 1,4-cyclohexanedicarboxylate; · Green Ingredients: 2,4-Dimethyl-3-cyclohexene-1-carbaldehyde, 2-tert-butyl-1-cyclohexyl acetate, (+-)-1-phenylethyl acetate, (2-methylbutoxy)allyl acetate, 4-methyl-3-decen-5-ol, diphenyl ether, (Z)-3-hexen-1-ol, and / or 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-1-one; Musk ingredients: 1,4-dioxa-5,17-cycloheptadecanedione, pentadecenolide, 3-methyl-5-cyclopentadecen-1-one, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta-g-2-benzopyran, (1S,1´R)-2-[1-(3´,3´-dimethyl-1´-cyclohexyl)ethoxy]-2-methylpropylpropanoate, pentadecanolide, and / or (1S,1´R)-[1-(3´,3´-dimethyl-1´-cyclohexyl)ethoxycarbonyl]methylpropanoate; Woody ingredients: 1-(octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)-1-ethanone, patchouli oil, terpene fraction of patchouli oil, (1´R,E)-2-ethyl-4-(2´,2´,3´-trimethyl-3´-cyclopenten-1´-yl)-2-buten-1-ol, 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol, methyl cedryl ketone, 5-(2,2,3-trimethyl-3-cyclopentenyl)-3-methylpentan-2-ol, 1-(2,3,8,8-tetramethyl-1,2,3,4,6,7,8,8a-octahydronaphthalen-2-yl)ethan-1-one, and / or isobornyl acetate; Other ingredients (e.g. amber, powdery spicy or watery): dodecahydro-3a,6,6,9a-tetramethyl-naphtho[2,1-b]furan and its stereoisomers, heliotropin, anisaldehyde, eugenol, cinnamaldehyde, clove oil, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal and / or 3-(3-isopropyl-1-phenyl)butanal.

[0271] The fragrance ingredients are not limited to the above, and in any case many other such ingredients are listed in reference books such as the book by S. Arctander, Perfume and Flavor Chemicals, 1969, Montclair, New Jersey, USA, or its latest edition, or other works of a similar nature, and in the patent literature in the field of fragrance. It is understood that the auxiliary ingredient may also be a compound known to release various types of fragrance compounds in a controlled manner. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14] [Table 1-15] [Table 1-16]

[0272] [Table 2-1] [Table 2-2] [Table 2-3]

[0273] Group I: The components of Table 1 constitute 2-85 wt% of the composition used according to the present disclosure. According to one embodiment, the composition used according to the present disclosure comprises the malodor antagonist system defined above in an amount constituting 6-70 wt%. According to another embodiment, the composition used according to the present disclosure comprises the malodor antagonist system defined above in an amount constituting 8-60 wt%. According to another embodiment, the composition used according to the present disclosure comprises the malodor antagonist system defined above in an amount constituting 8-46 wt%.

[0274] According to a particular embodiment of the present disclosure, the malodor receptor antagonist system (Group I) from the composition used according to the present disclosure comprises at least three components selected from Table 1. According to another embodiment, at least four, alternatively at least five, alternatively at least six, or at least eight components selected from Table 1 are part of the malodor receptor antagonist system.

[0275] Group II: Group II in the present disclosure is a functional blended fragrance as defined above. In some embodiments, the functional blended fragrance of Group II is present in an amount ranging from 15 to 98 wt% of the composition used according to the present disclosure. According to one embodiment, it is present in an amount ranging from 30 to 94 wt%. According to another embodiment, it is present in an amount ranging from 40 to 92 wt% of the composition. According to another embodiment, it is present in an amount ranging from 29 to 92 wt% of the composition.

[0276] According to a particular embodiment, Group II consists of one or more components from the group in Table 2.

[0277] Group III: According to a particular embodiment, the composition used according to the present disclosure comprises a non-functional perfume compound as defined above. The non-functional perfume compound consists of a fragrance ingredient as defined above that does not belong to either Group II or Group I. When present in a composition according to the present disclosure, the non-functional perfume compound may typically be included in an amount ranging from 0.5 to 70 wt %, alternatively 0.5 to 50 wt %, of the composition defined in any of the above embodiments presented herein.

[0278] Group IV-Delivery Systems: According to a particular embodiment, the composition defined above can be used in combination with a delivery system. The use of the delivery system allows the active ingredient in the composition to be at an optimal gas phase concentration. Delivery systems suitable for the purposes of the present disclosure include, but are not limited to: A passivated plated support comprising one or more of the following porous or non-porous substrates in loose powder or compressed form, the substrates being selected from the following non-limiting examples: cellulose (paper / cardboard), vermiculite, other industrial absorbents, perlite, calcium carbonate, pumice, other minerals, wood, sawdust, ground corn cobs, ground rice husks, rice husk ash, other agricultural by-products, biochar, starch, modified starch; Spray-dried, wet-activated encapsulation systems, in which a composition according to the present disclosure is encapsulated by a spray-drying process within a matrix containing one or more of, but not limited to, maltodextrin, starch octenyl succinate (modified starch); Core-shell encapsulation systems, such as mechanically activated microcapsules having an impermeable shell (e.g., polyurea, polyurethane, and others) and a composition according to the present disclosure in the core; Liquid mixtures containing surfactants; Polymer materials.

[0279] Therefore, the use of a composition as defined in any of the above aspects, further comprising an encapsulating material such as a polymer for forming microcapsules or microparticles, or a material for forming a liquid delivery system of the composition, such as an emulsion, microemulsion, miniemulsion, gel, microgel, anhydrous gel, or dispersion, is also an object of the present disclosure.

[0280] According to a particular embodiment, the composition defined in any of the above embodiments is in loose powder or compressed form, absorbed onto a porous or non-porous substrate, the substrate being selected from cellulose (paper / cardboard), vermiculite, other industrial absorbents, perlite, calcium carbonate, pumice, wood, sawdust, ground corn cob, ground rice husk, rice husk ash, biochar, starch, modified starch, and mixtures thereof.

[0281] A second object of the present disclosure is a malodor receptor antagonist system consisting of at least three, or at least four components selected from the group in Table 1.

[0282] Another object of the present disclosure is a malodor counteracting composition comprising: a) a malodor receptor antagonist system comprising at least one, or at least three components selected from Table 1 in an active amount of about 2 to about 85 wt %; b) a functional blended fragrance comprising about 15 to about 98 wt % of at least two components selected from the group consisting of components selected from Table 2; c) Optionally, a non-functional blend of fragrance ingredients comprising at least two fragrance ingredients.

[0283] According to a particular embodiment, the composition comprises from about 6 to about 70 wt % of Group I. According to another embodiment, the composition comprises from about 8 to about 60 wt % of Group I.

[0284] In some embodiments, the composition further comprises at least one other MOC compound.As used herein, the term "other MOC compound" refers to a material that is already known for MOC activity and is commonly used in the industry for that application.The inclusion of at least one other MOC compound can further enhance or complement the MOC activity of the at least one compound.

[0285] Non-limiting examples of the at least one other MOC compound include antimicrobial agents, malodor absorbers, chemical neutralizers (e.g., acid-base reagents), thiol scavengers, odor blockers, cross-adapting agents such as those disclosed in U.S. Pat. No. 5,538,719, which is incorporated herein by reference, and malodor complexing agents (e.g., various cyclodextrins).

[0286] Examples of antimicrobial agents include, but are not limited to, metal salts such as zinc citrate, zinc oxide, zinc pyrithione, and octopirox; organic acids such as sorbic acid, benzoic acid, and their salts; parabens such as methylparaben, propylparaben, butylparaben, ethylparaben, isopropylparaben, isobutylparaben, benzylparaben, and their salts; alcohols such as benzyl alcohol, phenylethyl alcohol; boric acid; 2,4,4'-trichloro-2-hydroxy-diphenyl ether; phenolic compounds such as phenol, 2-methylphenol, 4-ethylphenol; essential oils such as rosemary, thyme, lavender, eugenol, geranium, tea tree, clove, lemongrass, peppermint, or active ingredients thereof, such as anethole, thymol, eucalyptol, farnesol, menthol, limonene, methyl salicylate, salicylic acid, terpineol, nerolidol, geraniol, and the like, and mixtures thereof.

[0287] Examples of malodor absorbers include, but are not limited to, molecular sieves, such as zeolites, silica, aluminosilicates, and cyclodextrins; and organic absorbers, such as activated carbon, dried citrus pulp, cherry pit extract, corn cob, and mixtures thereof.

[0288] In some embodiments, the compositions described herein may comprise one or more of at least one compound described herein.Without intending to be limited to a particular theory, compositions comprising a plurality of at least one compound described herein may allow those skilled in the art to prepare MOC compositions with fine-tuned activity for targeted malodors or malodor sources.

[0289] For clarity, it is also understood that any mixture resulting directly from a chemical synthesis, such as a reaction medium without significant purification, that includes at least one compound as a starting material, intermediate, or end product cannot be considered a MOC composition in accordance with the present disclosure, unless the mixture provides at least one compound in a suitable form. Thus, unpurified reaction mixtures are generally excluded from the present disclosure, unless otherwise specified.

[0290] Moreover, at least one compound may be used in any consumer product that may be useful to have at least MOC activity.Therefore, another object of the present disclosure is represented by the MOC consumer product that comprises at least one composition as defined above as active ingredient.It is understood that MOC consumer product can also be fragrance-imparting in nature.

[0291] As used herein, a "MOC and optionally fragranced consumer product" or similar term refers to a consumer product that is expected to provide at least a MOC benefit and optionally also a pleasant fragrance benefit to a surface to which it is applied (e.g., skin, hair, fabric, or surfaces in the home, as well as air). In other words, a consumer product according to the present disclosure is a perfumed consumer product that includes a functional formulation, and optionally additional benefit agents, corresponding to a desired consumer product, such as a detergent or fragrance, and an effective amount of at least one compound of the present invention.

[0292] The nature and type of ingredients of MOC consumer products are not guaranteed to be described in further detail herein and are in no way exhaustive, but rather can be selected by a person skilled in the art on the basis of general knowledge and depending on the nature and desired effect of the product.

[0293] Non-limiting examples of suitable fragrance consumer products include: -Perfumes, such as perfumes, eau de toilette, cologne or aftershave; -Fabric care products, such as liquid detergent, detergent powder, detergent tablets, detergent bars, detergent paste, detergent pouches, liquid fabric softener, fabric softener sheets, fabric fragrance enhancers, laundry pre-treats, fabric deodorizers, ironing waters, laundry bleaches, carpet powders or carpet cleaners; - hair care products, such as shampoos, hair conditioners, hair creams, hair oils, hair styling products (such as sprays, mousses or gels), hair colour products or hair permanent wave products; -skin care products, such as face creams, face lotions, shaving products (such as foams, creams, gels, or oils), body and / or hand products (such as lotions, creams, gels, or oils), skin tightening products, depilatories, talcum powders, foot care creams or lotions, baby wipes, cleansing wipes, moisturizer wipes, sunscreen products (such as sprays, lotions, creams, or oils), after-sun lotions, or self-tanning products; - body deodorant or antiperspirant products, such as body deodorant spray, roll-on deodorant, deodorant stick, deodorant cream, antiperspirant spray, antiperspirant stick, roll-on liquid antiperspirant, antiperspirant stick, or antiperspirant cream; -Skin cleansing products, such as soap bars, shower gels, liquid hand soaps, bath foams or intimate cleansing products; - air freshening products, such as spray air fresheners, gel air fresheners, liquid wick air fresheners, solid air fresheners with a porous substrate (such as paper or card blotters, porous ceramic, or porous plastic), liquid or gel air fresheners with a permeable membrane, motorized air fresheners, and dual air freshener / disinfectant sprays; and / or -surface care products, such as all-purpose cleaners, furniture polishes, wood floor cleaners, window cleaners, hand dishwashing products (such as liquids, gels or pastes), machine dishwashing products (such as powders, liquids, gels, tablets or sachets), toilet bowl cleaning liquids, in-tank toilet cleaners, toilet rim blocks or toilet rim liquids; pet litter.

[0294] Some of the MOC consumer products mentioned above may be aggressive media for at least one compound and therefore may require protection of the compound from premature degradation, for example by encapsulation or by chemically binding to another chemical suitable for releasing the component of the invention under an appropriate external stimulus, such as an enzyme, light, heat or a change in pH.

[0295] In some embodiments, the composition defined in any of the above embodiments can be absorbed in loose powder or compressed form onto a porous or non-porous substrate selected from cellulose (paper / cardboard), vermiculite, other industrial absorbents, perlite, calcium carbonate, pumice, wood, sawdust, ground corn cobs, ground rice husks, rice husk ash, biochar, starch, modified starch, and mixtures thereof.

[0296] Thus, in some embodiments, the present disclosure provides a perfumed consumer product comprising an effective amount of at least one compound. In some embodiments, the perfumed consumer product is selected from the group consisting of an air freshening product, a home care product, and a laundry care product.

[0297] In some embodiments, the perfumed consumer product comprising an effective amount of at least one compound comprises a formulation selected from the group consisting of aerosol and / or water-based air freshener sprays, wick / lead air fresheners, liquid electric (plug-in) air fresheners, solid supported air fresheners, gel-based air fresheners, membrane-encapsulated air fresheners, bleaching, cleaning, washing powder detergents, liquid all-purpose cleaners, specialty cleaners, and liquid detergents.

[0298] Those skilled in the art will appreciate that the concepts and specific embodiments disclosed may be readily utilized as a basis for modifying or formulating other formulations for carrying out the same purposes of the present invention, and will also recognize that such equivalent formulations do not depart from the spirit and scope of the disclosure as set forth herein.

[0299] The ratio that the at least one compound can be incorporated into various aforementioned products or compositions varies within a wide range of values.Such values ​​vary depending on the nature and desired organoleptic effect of the MOC consumer product, as well as the nature of the auxiliary components in a given composition when the at least one compound is mixed with other components, solvents, or additives commonly used in the art.

[0300] In general, for example, in fragrance compositions, typical concentrations of the at least one compound are on the order of 0.001% to 5% by weight, or more, based on the weight of the composition in which the compound is incorporated. When the compositions described herein are incorporated into MOC consumer products, lower concentrations can be used, for example, on the order of 0.01% to 100% by weight relative to the weight of the consumer product.

[0301] In particular, the concentration of the MOC composition according to the embodiments described herein used in the various aforementioned consumer products varies within a wide range of values ​​depending on the nature of the consumer product. For example, the MOC composition according to some embodiments described herein can be used in fragrance products at a concentration of 0.01% to 50% by weight, alternatively at a concentration of 0.2% to 40% by weight, alternatively at a concentration of 0.5% to 25% by weight. For example, the MOC composition according to some embodiments described herein can be used in fabric care products at a concentration of 0.01% to 20% by weight, alternatively at a concentration of 0.05% to 10% by weight, alternatively at a concentration of 0.1% to 5% by weight. Further, for example, the MOC composition according to some embodiments described herein can be used in hair care products at a concentration of 0.01% to 10% by weight, alternatively at a concentration of 0.05% to 5% by weight, alternatively at a concentration of 0.1% to 3% by weight. For example, the MOC composition according to some embodiments described herein can be used in skin care products at a concentration of 0.01% to 10% by weight, alternatively at a concentration of 0.05% to 5% by weight, more preferably at a concentration of 0.1% to 2.5% by weight. For example, the MOC composition according to some embodiments described herein can be used in body deodorant or antiperspirant products at a concentration of 0.01% to 10% by weight, alternatively at a concentration of 0.05% to 7% by weight, alternatively at a concentration of 0.1% to 5% by weight. Further, for example, the MOC composition according to some embodiments described herein can be used in skin cleansing products at a concentration of 0.01% to 5% by weight, alternatively at a concentration of 0.05% to 3% by weight, alternatively at a concentration of 0.1% to 2.5% by weight. For example, the MOC composition according to some embodiments described herein can be used in air freshening products at a concentration of 0.01% to 100% by weight. For example, MOC compositions according to some embodiments described herein can be used in surface care products at a concentration of 0.001% to 10% by weight, alternatively at a concentration of 0.01% to 5% by weight, or alternatively at a concentration of 0.1% to 2% by weight.Further for example, MOC compositions according to some embodiments described herein can be used in pet litter products at a concentration of 0.001% to 1% by weight, alternatively at a concentration of 0.005% to 0.5% by weight, or alternatively at a concentration of 0.01% to 0.3% by weight.

[0302] The present invention will now be described in detail with reference to the best mode thereof, but is not limited to the following examples.

[0303] Working Example Example 1: Identification of Geonol Olfactory Receptor Inhibitors Cell-based screening: Cell lines expressing either the OR11A1 or OR2M3 olfactory receptors were used as antagonist screening platforms to identify compounds with properties that reduce geonol-induced receptor activity. A volatile compound library was used to screen each cell line for inhibitory properties and potential geonol odor inhibition. First, binary mixtures of geonol and one of the test compounds were individually presented to the cells.

[0304] Single-point monitoring of Geonol-induced cellular activity in the presence or absence of test compounds allowed the identification of compounds with putative suppressive or inhibitory effects. The hit compounds were further confirmed in an inhibition dose-response curve assay, and the potency of activity inhibition was measured using IC 50 The half-maximal inhibitory efficacy level was evaluated as a measure of the inhibitor concentration at which receptor activity was inhibited by a given test compound.

[0305] A single activation concentration of Geonol (EC 80 Increasing concentrations of test compounds were used in the presence of 5-aminoethyl-1,1-diphenylmethane (DMSO) and the dose-dependent decrease in receptor activity was recorded and the corresponding dose-response inhibition curves were obtained. The compounds listed in Table 2 are examples of compounds that decreased geonol-induced activation of at least one olfactory receptor.

[0306] Sensory evaluation:Panelists were presented with five 16-ounce glass jars containing either the REF (geonol only), a geonol only control, antagonist only, a mixture of geonol and an equal strength antagonist, or a mixture of geonol and a low strength antagonist (the last four samples were randomized among panelists). Panelists were first asked to acclimate to the earthy / mossy odor of the REF jar, and then judged the pleasantness, earthy / mossy odor intensity, and overall odor intensity of the four subsequent samples on a linear scale of 0 to 10. To avoid acclimatization, there was a 2-minute stimulation interval between samples. The results are superimposed in Figure 4, which shows the ratio of geonol malodor (earthy / mossy) remaining in the equal strength binary mixtures of geonol and 25 antagonists relative to the REF samples.

[0307] One-way analysis of variance (ANOVA) with Duncan's mean comparison at the 95% confidence level was performed to compare the mean earthy / mossy odor intensity between geonol-only samples, antagonist-only samples, and the two ratios of geonol reference / antagonist mixtures. The results from the cell-based screening and sensory evaluation are shown in Table 3 and Figure 2.

[0308] * means that the earthy / mossy odor of the mixture of equal strengths of geonol and antagonist was significantly lower than the geonol only sample at the 95% confidence level. NS means that there was no significant difference in the earthy / mossy odor intensity between the equal strength mixture and the geonol only sample at the 95% confidence level. NT indicates that the antagonist was not tested in the human sensory test. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7]

[0309] Example 2: Identification of 1-octen-3-ol olfactory receptor inhibitors Cell lines expressing either the OR2W1 or OR1A1 olfactory receptors were used as antagonist screening platforms to identify compounds with properties that reduce 1-octen-3-ol-induced receptor activity. A volatile compound library was used to screen each cell line for inhibitory properties and potential for 1-octen-3-ol odor inhibition. First, binary mixtures of 1-octen-3-ol and one of the test compounds were presented to the cells individually.

[0310] Single concentration monitoring of 1-octen-3-ol-induced cellular activity in the presence or absence of test compounds allowed the identification of compounds with putative suppressive or inhibitory effects. The hit compounds were further confirmed in an inhibition dose-response curve assay, and the potency of activity inhibition was measured using IC 50 The inhibitor concentration at which receptor activity is inhibited by a given test compound at the half-maximal inhibitory efficacy level was measured and assessed as % maximal inhibition (normalized to baseline agonist activity).

[0311] A single activation concentration of 1-octen-3-ol (EC 80 Increasing concentrations of test compound were used in the presence of 1-octen-3-ol, and dose-dependent decreases in receptor activity were recorded, yielding corresponding dose-response inhibition curves. The compounds listed in Table 4 are examples of compounds that decreased 1-octen-3-ol-induced activation of at least one receptor. [Table 4-1] [Table 4-2] [Table 4-3]

[0312] Example 3: Identification of butyric acid olfactory receptor inhibitors A cell line expressing the OR51E1 olfactory receptor was used as an antagonist screening platform to identify compounds with properties that reduce butyrate-induced receptor activity. A volatile compound library was used to screen the stable cell line for inhibitory properties and potential for butyrate odor inhibition. First, a binary mixture of butyrate and one of the test compounds was presented to the cells individually.

[0313] Single concentration monitoring of butyrate-induced cellular activity in the presence or absence of test compounds allowed the identification of compounds with putative suppressive or inhibitory effects. The hit compounds were further confirmed in an inhibition dose-response curve assay, and the potency of activity inhibition was measured using IC 50 The inhibitor concentration at which receptor activity is inhibited by a given test compound at the half-maximal inhibitory efficacy level was measured and assessed as % maximal inhibition (normalized to baseline agonist activity).

[0314] A single activation concentration of butyrate (EC 80 Increasing concentrations of test compound were used in the presence of 5-aminobutyric acid (Ab) and the dose-dependent decrease in receptor activity was recorded and a corresponding dose-response inhibition curve was obtained. The compounds listed in Table 5 are examples of compounds that decreased butyrate-induced activation of at least one receptor. [Table 5-1] [Table 5-2]

[0315] Example 4: Compositions according to some embodiments presented herein The following table represents compositions according to the present disclosure.

Table 6

Table 7-1

Table 7-2

Table 8-1

Table 8-2

Table 9-1

Table 9-2

Table 10-1

Table 10-2

Table 11-1

Table 11-2

Table 12-1

Table 12-2

Table 13-1

Table 13-2

Table 14

Table 15

[0316] Example 5: Sensory Measurement of Residual Malodor Scores for Individual Malodor Receptor Antagonist Systems, Individual Functional Fragrance Ingredients, and Compositions According to the Present Disclosure The malodor receptor antagonist system and compositions were evaluated at a gas phase concentration of 3.4 μg / l (air). The sensory method for evaluating the compositions involved the use of a specially designed air dilution olfactometer to adequately control and stabilize the gas phase concentrations of the compositions and malodors delivered to the test subject groups.

[0317] Thirty subjects first rated the malodor reconstructions alone and then judged the three attributes "freshness", "pleasantness" and "malodor" (malodor characteristics) on a scale of 0 to 10. To avoid odor adaptation, the next evaluation was performed after 30 seconds. The malodor reconstructions were injected into the olfactometer together with the test composition. Scores were recorded for identical descriptive words.

[0318] The results are shown in Tables 16 and 17 and Figures 3 to 5.

[0319] The malodor reconstitution model for fecal malodors is a fecal reconstitution composed of indole, methyl mercaptan, p-cresol, and butyric acid. The gas-phase concentrations of the fecal malodor reconstitution and its components are consistent with headspace analysis results from gas-phase sampling of toilets (Charles JF Chappuis, Yvan Niclass, Christine Vuilleumier, and Christian Starkenmann Quantitative Headspace Analysis of Selected Odorants from Latrines in Africa and India Environ. Sci. Technol. 2015, 49, 6134-6140).

[0320] The results are expressed as the average score of the three descriptors for the particular malodor reconstitution alone and for the particular malodor reconstitution in combination with the test composition. [Table 16-1] [Table 16-2] [Table 16-3] [Table 16-4] [Table 16-5] [Table 16-6] [Table 16-7] [Table 16-8] [Table 17-1] [Table 17-2] [Table 17-3] [Table 17-4] [Table 17-5] [Table 17-6] [Table 17-7] [Table 17-8]

[0321] Example 6: Malodor Reduction Efficacy Testing of Candles Containing Fragrance Compositions According to the Present Disclosure The air freshener device used in this example is a candle. Such a device delivers scent by two means. First, the fragrance incorporated in the candle slowly evaporates as it travels through the wax and onto the surface of the candle. The second means is by a much more diffusive "melt pool." Melt pooling occurs during candle lighting when a portion of the candle melts in the flame and forms a pool at the top. The warmed mixture is expected to deliver a higher proportion of the scent.

[0322] Scented candles are made by mixing the fragrance composition in the candle composition shown in the table below. 100 grams of the wax mixture is placed in a 3 inch tall, 3 inch diameter circular glass container with a wax covered felt wick (CD#6, cut to 0.5 inch height). An unscented candle is made as a test sample containing only malodors (Candle wax 4625A IGI, 88%). [Table 18] [Table 19]

[0323] The sensory cabins are evaluated by 15 untrained but experienced assessors. Data are analyzed by one-way analysis of variance (ANOVA) followed by Fisher's least significant difference (LSD) method for multiple comparisons (α=0.05). The number of assessors (N) and LSD are as follows: N=15, LSD=0.70.

[0324] Example 7: Malodor Reduction Efficacy Testing of Aerosol Air Fresheners Containing Fragrance Compositions According to the Present Disclosure The fragrance device used in this example is an aerosol: such devices deliver scent into the environment by means of pressurized aqueous scented solutions.

[0325] The scented aerosols are made by mixing the fragrance compositions in the aerosol compositions shown in the table below. [Table 20]

[0326] The sensory cabins are evaluated by 15 untrained but experienced assessors. Data are analyzed by one-way analysis of variance (ANOVA) followed by Fisher's least significant difference (LSD) method for multiple comparisons (α=0.05). The number of assessors (N) and LSD are as follows: N=15, LSD=0.70.

[0327] Example 8: Malodor reduction efficacy test of sachet-type air fresheners containing fragrance compositions according to the present disclosure The air freshener device used in this example is a sachet-type air freshener. Such devices utilize a granular substrate impregnated with fragrance contained within a permeable pouch made from paper, woven, or nonwoven material.

[0328] Scented sachets are made by mixing the fragrance composition with ground corncob particles (NatureZorb®-100, manufactured by Aproa) at a loading of 20% by weight. 12 grams of the resulting mixture are then placed into a 2.5" x 2.5" paper pouch. A sample containing unscented corncob is made for cabin odor only.

[0329] The sensory cabins are evaluated by 15 untrained but experienced assessors. Data are analyzed by one-way analysis of variance (ANOVA) followed by Fisher's least significant difference (LSD) method for multiple comparisons (α=0.05). The number of assessors (N) and LSD are as follows: N=15, LSD=0.70.

[0330] Example 9: Malodor reduction efficacy test of liquid-type air fresheners containing fragrance compositions according to the present disclosure The fragrance device used in this example is an electronic wick fragrance device. Such devices utilize a heating element to deliver the fragrance composition from a wick inserted into a fragranced reservoir.

[0331] The fragrance composition is mixed with an equal part by weight of Augeo Clean Multi (Solvay). Then, 20 grams of the resulting mixture is placed in a reservoir (sintered plastic) equipped with a wick. The heater device used is designed to heat the wick to 70°C.

[0332] The sensory cabins are evaluated by 15 untrained but experienced assessors. Data are analyzed by one-way analysis of variance (ANOVA) followed by Fisher's least significant difference (LSD) method for multiple comparisons (α=0.05). The number of assessors (N) and LSD are as follows: N=15, LSD=0.70.

[0333] Example 10: Malodor Reduction Efficacy Testing of Bleach Powders Containing Fragrance Compositions According to the Present Disclosure The malodor reduction of the fragrance composition described by this disclosure is measured in bleach cleaning powder.Bleach cleaning powder is a bleach powder mixed with spray-dried fragrance.The standard method of using this product is to apply the powder to the area to be treated, dissolve it with water, scrub to break apart all particles, and then rinse.

[0334] The scented bleach sample is prepared by adding 0.15 grams of the spray dried powder (composed of 50% (w / w) perfume, 50% (w / w) octenyl succinate modified starch) to 9.85 grams of Stable Bleaching Powder (Grade I, Gujarat Alkalies and Chemicals Limited, Gujarat, India).

[0335] The malodor reconstitution is added to fine vermiculite (Specialty Vermiculite Corp, Enoree, SC) at a loading of 70% by weight. 9 grams of the test composition are then placed in a round aluminum can and presented to the evaluator. The aluminum can is 3 inches in diameter and 1 inch in height. For scented test samples only, the can containing untreated vermiculite is used.

[0336] Vermiculite loaded with 70% by weight of toilet malodor was prepared by blending 350 g of toilet malodor with 150 g of vermiculite (fine granules, Specialty Vermiculite Corp, Enoree, SC). The efficacy of cellulosic air fresheners including fragrance formulations according to the present disclosure is evaluated according to the procedure described in ASTM E 1593-06 "Method for Assessing the Efficacy of Air Care Products in Reducing Sensorialy Perceived Indoor Air Malodor Intensity". First, evaluators are presented with a booth labeled "reference" containing only a can of malodor for acclimatization to the malodor. Then, using a scale of 1 to 7 (1 indicating no odor, 4 indicating moderate odor, and 7 indicating very strong malodor), the evaluators evaluate each sample in the specified order to determine the malodor intensity and overall odor intensity.

[0337] The samples were evaluated by 19 untrained evaluators, by which we mean those without formal olfactory training, who are accustomed to participating in fragrance evaluations and who are users of fragrances with experience in judging odor attributes.

[0338] 60 ft 3The evaluation chamber is used, the cabin floor is wetted with water and the samples are rubbed on the floor until dissolved. The malodor reconstruction is then added. Environmental conditions during the test are 72F, 40% RH with 5 air changes per hour. A portable tabletop fan set to low is placed on the cabin floor to circulate the air in the room. The booths are labeled with randomly generated 3-digit codes. Sample presentation is blinded, distributed, randomized sequential monadic. Five minutes after activation, the assessor is instructed to evaluate each sample by opening the sniff window, waits 60 seconds, and then proceeds to answer a series of questions about the odors perceived in the room. The assessor is asked to judge the malodor intensity and the overall odor intensity. Data are analyzed using analysis of variance (ANOVA) and the least significant difference is used to determine the difference between two means (α=0.05).

[0339] Example 11: IC50 values ​​of the compounds presented herein for various olfactory receptors The malodor reduction of the fragrance composition described by this disclosure is measured in bleaching cleaning powder.Bleaching cleaning powder is a bleaching powder mixed with spray-dried fragrance.The standard method of using this product is to apply the powder to the area to be treated, dissolve it with water, scrub to break apart all particles, and then rinse. [Table 21-1] [Table 21-2] [Table 21-3] [Table 21-4] [Table 21-5] [Table 21-6] [Table 21-7]

Table 21-8

Table 21-9

Table 21-10

Table 21-11

Table 21-12

Table 21-13

Table 22-1

Table 22-2

Table 22-3

Table 22-4

Table 22-5

Table 22-6

Table 23-1

Table 23-2

Table 23-3

Table 23-4

Table 24-1

[0340] Example 12: Identification of antagonists of the indole / skatole olfactory receptor Functional dose-response experiments were performed to identify compounds capable of antagonizing the previously identified indole-sensitive receptor (US Pat. No. 9,914,760). Using a cell-based assay, mouse receptors Olfr738, Olfr739, Olfr740, Olfr741, Olfr742, Olfr743, Olfr744, Olfr746, Olfr748, and Olfr749 were tested in the HEK293T cell line, which has an activated endogenous RTP1 gene and expresses odorant receptor chaperones (described in WO2016201153). The receptor gene was tagged with a Flag-Rho tag combination. The receptor gene was tagged with the canonical olfactory human G protein alpha subunit G olf The gene was co-transfected with human G olf Co-expression of Gs activates the Gs transduction pathway, which leads to an increase in internal cAMP upon binding of the appropriate ligand (herein, indole). Odorant-induced activity was detected by measuring the cytosolic cAMP increase using an HTRF-based kit (CisBio, cAMP dynamic 2 kit, Cat. No. 62AM4PEJ). A potent activating concentration of indole (EC 80 The receptors were exposed to increasing concentrations of the binary mixture of the test compound in the presence of 100 μg / mL ... 50 (the inhibitor concentration at which receptor indole activity is inhibited at the half-maximal inhibitory efficacy level) and the maximum inhibition rate (%) (baseline indole EC 80 The following table shows the IC of each compound across all receptors. 50The dose-dependent inhibition curves and the inhibition percentages are summarized in Tables 22 and 23. All of the compounds listed reduced the indole-induced activation of at least one receptor. Representative dose-dependent inhibition curves are shown in Figures 6-9. [Table 25-1] [Table 25-2] [Table 26-1] [Table 26-2]

[0341] Although various aspects of the present invention have been illustrated above with reference to examples and preferred embodiments, it will be understood that the scope of the present invention is defined not by the foregoing description but by the following claims, appropriately interpreted under the principles of patent law.

Claims

1. 1. A method for inhibiting, reducing, or suppressing the perception of malodor in a subject, comprising the steps of: (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-3,6,8,8-tetramethyloctahydro-1H-3a,7-methanoazulen-6-ol, nona-2,6-dienal, (+-)-perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, (1RS,2SR,5RS,7RS,8SR)-5-methyltricyclo[6.2.1.0-2,7-]undecan-4-one (A ) and (1RS,2SR,5SR,7RS,8SR)-5-methyltricyclo[6.2.1.0-2,7-]undecan-4-one (B), ethyl 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, mixture of 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene and 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, ethyl 4,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, (2-methyl-2-indanyl) (R)-methyl acetate, 2-pentylcyclopentan-1-one, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexanone, mixture of 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one and 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, phenethyl alcohol, diethyl 1,4-cyclohexanedicarboxylate, (+)-(R)-3,7-dimethyl-6- Octenal, a mixture of 3,5,6-trimethyl-3-cyclohexene-1-carbaldehyde (A) and 2,4,6-trimethyl-3-cyclohexene-1-carbaldehyde (B), 3,7-dimethylocta-2,6-dienal, a mixture of 3-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde (A) and 4-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde, 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one and 1-(2,6,Mixture of (4Z,8E)-13-oxabicyclo[10.1.0]trideca-4,8-diene, (4E,8E)-4,8-cyclododecadien-1-one (A), (4E,8Z)-4,8-cyclododecadien-1-one (B) and (4Z,8E)-4,8-cyclododecadien-1-one (C), (1R,4Z,8E,12R)-13-oxabicyclo[10.1.0]trideca-4,8-diene, A mixture of chloro[10.1.0]trideca-4,8-diene and (4Z,8E)-13-oxabicyclo[10.1.0]trideca-4,8-diene, 2,2,7,7-tetramethyltricyclo[6.2.1.0-1,6-]undecan-6-ol, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 8,8-dimethyl-2,3,4,6,7,8-{a}-hexahydro-1-{H}-naphthalene-2-carbaldehyde and 8,8-dimethyl-2,3,5,6,7,8-{a}-hexahydro-1-{H}-naphthalene-2-carbaldehyde. A mixture of 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one and 1-(2,4-dimethyl-1,2-dimethyl-1,4-dimethyl-1,5-dimethyl-1,6-dimethyl-1,7-dimethyl-1,8-dimethyl-2,3,4,5,6,7-hexahydro-1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one, and 1-(2,4-dimethyl-1,2-dimethyl-1,5-dimethyl-1,6-dimethyl-1,7-dimethyl-1,8-dimethyl-1,7-dimethyl-1,8-dimethyl-1,9 ... Mixture of (5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, (5RS,6RS)-2,6,10,10-tetramethyl-1-oxaspiro[4.5]decan-6-ol, (2,2,2-trichloro-1-phenylethyl)acetate, patchouli oil, (1-{S},3-{S},6-{R},7-{R},8-{S})-2,2,6,8-tetramethyltricyclo[5.3.1.0^{3,8}]undecan-3-ol, (4S,4aS,8aR)-4,8a-dimethyl-1,2,3,4,5,6,7,contacting the subject with at least one compound selected from the group consisting of: octahydronaphthalene-4a-ol, octahydronaphthalene-4a-ol, and combinations thereof; contacting said at least one compound in an amount sufficient to inhibit, reduce, or inhibit the perception of malodor by said subject; said contacting inhibits at least one olfactory receptor in said subject; The method, wherein said at least one olfactory receptor is a DMTS olfactory receptor.

2. 1. A method for inhibiting at least one olfactory receptor in a subject, comprising the steps of: (+-)-(3E)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (+-)-3,6,8,8-tetramethyloctahydro-1H-3a,7-methanoazulen-6-ol, nona-2,6-dienal, (+-)-perhydro-5,5,8A-trimethyl-2-trans-naphthalenone, (1RS,2SR,5RS,7RS,8SR)-5-methyltricyclo[6.2.1.0-2,7-]undecan-4-one (A); and (1RS,2SR,5SR,7RS,8SR)-5-methyltricyclo[6.2.1.0-2,7-]undecan-4-one (B), ethyl 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, mixture of 1,4,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene and 1,5,8-trimethyl-13-oxabicyclo[10.1.0]trideca-4,8-diene, ethyl 4,6,6-trimethyl-1,3-cyclohexadiene-1-carboxylate, (2-methyl-2-indanyl) (R)-methyl acetate, 2-pentylcyclopentan-1-one, (+-)-1-(2,5-dimethyl-2,3-dihydro-1H-inden-2-yl)ethanone, 4-(1,1-dimethylpropyl)-1-cyclohexanone, mixture of 4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one and 4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one, phenethyl alcohol, diethyl 1,4-cyclohexanedicarboxylate, (+)-(R)-3,7-dimethyl-6- Octenal, a mixture of 3,5,6-trimethyl-3-cyclohexene-1-carbaldehyde (A) and 2,4,6-trimethyl-3-cyclohexene-1-carbaldehyde (B), 3,7-dimethylocta-2,6-dienal, a mixture of 3-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde (A) and 4-(4-methyl-3-pentenyl)-3-cyclohexene-1-carbaldehyde, 3-methyl-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one and 1-(2,6,Mixture of (4Z,8E)-13-oxabicyclo[10.1.0]trideca-4,8-diene, (4E,8E)-4,8-cyclododecadien-1-one (A), (4E,8Z)-4,8-cyclododecadien-1-one (B) and (4Z,8E)-4,8-cyclododecadien-1-one (C), (1R,4Z,8E,12R)-13-oxabicyclo[10.1.0]trideca-4,8-diene, A mixture of chloro[10.1.0]trideca-4,8-diene and (4Z,8E)-13-oxabicyclo[10.1.0]trideca-4,8-diene, 2,2,7,7-tetramethyltricyclo[6.2.1.0-1,6-]undecan-6-ol, (2,5-dimethyl-1,3-dihydroinden-2-yl)methanol, 8,8-dimethyl-2,3,4,6,7,8-{a}-hexahydro-1-{H}-naphthalene-2-carbaldehyde and 8,8-dimethyl-2,3,5,6,7,8-{a}-hexahydro-1-{H}-naphthalene-2-carbaldehyde. A mixture of 1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one and 1-(2,4-dimethyl-1,2-dimethyl-1,4-dimethyl-1,5-dimethyl-1,6-dimethyl-1,7-dimethyl-1,8-dimethyl-2,3,4,5,6,7-hexahydro-1-(3,3-dimethylcyclohexen-1-yl)pent-4-en-1-one, and 1-(2,4-dimethyl-1,2-dimethyl-1,5-dimethyl-1,6-dimethyl-1,7-dimethyl-1,8-dimethyl-1,7-dimethyl-1,8-dimethyl-1,9 ... Mixture of (5,5-dimethylcyclohexen-1-yl)pent-4-en-1-one, (5RS,6RS)-2,6,10,10-tetramethyl-1-oxaspiro[4.5]decan-6-ol, (2,2,2-trichloro-1-phenylethyl)acetate, patchouli oil, (1-{S},3-{S},6-{R},7-{R},8-{S})-2,2,6,8-tetramethyltricyclo[5.3.1.0^{3,8}]undecan-3-ol, (4S,4aS,8aR)-4,8a-dimethyl-1,2,3,4,5,6,7,contacting the subject with at least one compound selected from the group consisting of: octahydronaphthalene-4a-ol, octahydronaphthalene-4a-ol, and combinations thereof; The at least one olfactory receptor is a DMTS olfactory receptor; and contacting said at least one compound in an amount sufficient to inhibit said at least one olfactory receptor.

3. 3. The method of claim 2, wherein inhibition of at least one olfactory receptor inhibits, reduces or suppresses the perception of malodor in a subject.

4. 4. The method of claim 1 or 3, wherein the malodor is selected from the group consisting of toilet malodor, laundry malodor, mold malodor, and sweat malodor.

5. 3. The method of claim 1 or 2, wherein the DMTS olfactory receptor is selected from the group consisting of OR4S2 olfactory receptor, OR52N5 olfactory receptor, OR2L13 olfactory receptor, OR2AJ1 olfactory receptor, OR4C15 olfactory receptor, OR5AC2 olfactory receptor, OR8H3 olfactory receptor, OR11G2 olfactory receptor, OR52N2 olfactory receptor, OR5T1 olfactory receptor, Olfr1193 olfactory receptor, Olfr1093 olfactory receptor, Olfr1097 olfactory receptor, Olfr166 olfactory receptor, Olfr169 olfactory receptor, Olfr738 olfactory receptor, Olfr742 olfactory receptor, Olfr207 olfactory receptor, Olfr665 olfactory receptor, Olfr669 olfactory receptor, and Olfr1211 olfactory receptor.

6. The method of claim 1 or 2, wherein said at least one compound is incorporated into a fragrance composition.

7. The fragrance composition comprises a malodor receptor antagonist system comprising at least one malodor receptor antagonist and a non-functional blended fragrance; 7. The method of claim 6, wherein the non-functional perfume blend is at least one fragrance ingredient that does not act as a malodor counteractant.

8. The fragrance composition comprises: (i) a malodor receptor antagonist system comprising 2 wt% to 85 wt% of at least one malodor receptor antagonist; and (ii) 15 wt % to 98 wt % of a functional blended fragrance containing at least two fragrance ingredients, the blended fragrance having a fragrance note selected from floral, citrus, and jasmine. Including, 7. The method of claim 6, wherein the functional blended fragrance is a mixture of at least two fragrance ingredients that act on at least one component of malodor.

9. The method of claim 6 , wherein the fragrance composition is incorporated into a consumer product.

Images